



ISPOR 20th Annual  
International Meeting

May 16-20, 2015  
Philadelphia Marriott Downtown  
Philadelphia, PA, USA



# Research Poster Presentations – Session IV

Tuesday, May 19, 2015

3:45PM-7:45PM

**Poster Author Discussion Hour:**

6:45PM-7:45PM

Research Poster Presentations – Session IV includes the following topics

**PCN – CANCER** Rows A-J

**PGI – GASTROINTESTINAL DISORDERS** Rows J-L

**PIN – INFECTION** Rows L-V

---

A1 Location of the poster in the poster hall – please refer to last page for a floor plan

pgA10 Location of the abstract as published in *Value in Health* Volume 18, Issue 3

# RESEARCH POSTER PRESENTATIONS - SESSION IV

## DISEASE- SPECIFIC STUDIES

### CANCER - Clinical Outcomes Studies

- PCN1 A1 pgA190 BONE SAFETY PROFILE OF DENOSUMAB THERAPY: A PHARMACOVIGILANCE CHARACTERIZATION ANALYSIS**  
Ali AK, Eli Lilly and Company, Indianapolis, IN, USA
- PCN2 A2 pgA190 META-ANALYSIS OF THE SAFETY OF SIPULEUCEL-T IMMUNOTHERAPY IN PROSTATE CANCER**  
Ma J<sup>1</sup>, Xuan S<sup>2</sup>, Tak C<sup>1</sup>, Brixner D<sup>1</sup>,<sup>1</sup>University of Utah, Salt Lake City, UT, USA, <sup>2</sup>Yale University, New Haven, CT, USA
- PCN3 A3 pgA190 TREATMENT FOR CHEMOTHERAPY-RELATED COGNITIVE DYSFUNCTION: REVIEW OF THE LITERATURE**  
Meyers OI, Truven Health Analytics, Cambridge, MA, USA
- PCN4 A4 pgA190 HYPOFRACTIONED RADIOTHERAPY IN THE TREATMENT OF EARLY BREAST CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS**  
Andrade TR<sup>1</sup>, Segreto H<sup>2</sup>, Segreto R<sup>2</sup>, Nazario A<sup>2</sup>, Fonseca M<sup>2</sup>,<sup>1</sup>AxiaBio, São Paulo, Brazil, <sup>2</sup>Federal University of São Paulo, São Paulo, Brazil
- PCN5 A5 pgA190 RISK OF CARDIOTOXICITY AND ALL-CAUSE MORTALITY IN BREAST CANCER PATIENTS AFTER ADJUVANT CHEMOTHERAPY OR HORMONAL THERAPY**  
Wittayanukorn S<sup>1</sup>, Qian J<sup>2</sup>, Westrick SC<sup>2</sup>, Billor N<sup>3</sup>, Johnson B<sup>4</sup>, Hansen RA<sup>2</sup>,<sup>1</sup>Auburn University, Harrison School of Pharmacy, Auburn, AL, USA, <sup>2</sup>Auburn University, Auburn, AL, USA, <sup>3</sup>Auburn University, College of Sciences and Mathematics, Auburn, AL, USA, <sup>4</sup>East Alabama Medical Center; Edward via College of Osteopathic Medicine, Opelika, AL, USA
- PCN6 A6 pgA190 RACIAL/ETHNICITY DISPARITIES IN THE ASSOCIATION BETWEEN DIABETES AND PANCREATIC CANCER IN THE ELDERLY MEDICARE POPULATION**  
Lu K<sup>1</sup>, Yuan J<sup>1</sup>, Li M<sup>1</sup>, Wu J<sup>2</sup>,<sup>1</sup>University of South Carolina, Columbia, SC, USA, <sup>2</sup>University of South Carolina, Greenville, SC, USA
- PCN7 A7 pgA191 COMORBIDITY AND POSTOPERATIVE OUTCOMES AMONG LUNG CANCER PATIENTS IN THE UNITED STATES**  
Nadpara PA, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA
- PCN8 A8 pgA191 INCREASED PREVALENCE OF LIPID DISORDERS IN CANCER PATIENTS ADMITTED TO U.S. HOSPITALS**  
Delgado A<sup>1</sup>, Villarreal SM<sup>1</sup>, Koeller JM<sup>1</sup>, Frei BL<sup>2</sup>, Frei CR<sup>1</sup>,<sup>1</sup>The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA, <sup>2</sup>University of the Incarnate Word, San Antonio, TX, USA
- PCN9 A9 pgA191 PRE-EXISTING TYPE 2 DIABETES MELLITUS AND EMERGENCY COLORECTAL SURGERY AMONG ELDERLY MEDICARE BENEFICIARIES WITH COLORECTAL CANCER**  
Deb A, Madhavan SS, Bose S, Sambamoorthi U, West Virginia University, Morgantown, WV, USA
- PCN10 A10 pgA191 PATTERNS OF CARE IN THE WORKUP AND MANAGEMENT OF NON-METASTATIC AND METASTATIC COLORECTAL CANCER**  
Seal B<sup>1</sup>, Shermock KM<sup>2</sup>, Asche CV<sup>3</sup>, Kreilick C<sup>1</sup>, Tangirala M<sup>1</sup>, Cameron J<sup>1</sup>, Kish J<sup>4</sup>, Zagadailov EA<sup>4</sup>, Eaddy M<sup>4</sup>,<sup>1</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, <sup>2</sup>The Johns Hopkins Medical Institutions, Baltimore, MD, USA, <sup>3</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>4</sup>Xcenda, Palm Harbor, FL, USA
- PCN11 A11 pgA191 THE BURDEN OF AML WITHIN THE <65 YEAR-OLD US POPULATION MAY BE HIGHER THAN ACCEPTED US REGISTRY ESTIMATES**  
Turbeville S<sup>1</sup>, Francis KM<sup>2</sup>, Behm I<sup>2</sup>, Chiu GR<sup>2</sup>, Sanchez H<sup>2</sup>, Morgan J<sup>1</sup>, Yakovich A<sup>1</sup>, Ward R<sup>1</sup>, Hyare P<sup>1</sup>,<sup>1</sup>Sunesis Pharmaceuticals, South San Francisco, MA, USA, <sup>2</sup>Trinity Partners, Waltham, MA, USA
- PCN13 A12 pgA192 UNDERSTANDING QALY GAINS ACROSS DIFFERENT TYPES OF CANCERS AND CANCER-RELATED INTERVENTIONS**  
Thorat T<sup>1</sup>, Chambers J<sup>1</sup>, Neumann PJ<sup>2</sup>,<sup>1</sup>Tufts Medical Center, Boston, MA, USA, <sup>2</sup>Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
- PCN14 A13 pgA192 COMPARATIVE EFFECTIVENESS OF EVEROLIMUS VS. FULVESTRANT MONOTHERAPY AMONG POSTMENOPAUSAL WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER**  
Lin PL<sup>1</sup>, Hao Y<sup>2</sup>, Xie J<sup>3</sup>, Li N<sup>1</sup>, Ohashi E<sup>1</sup>, Koo V<sup>1</sup>, Wu EQ<sup>1</sup>,<sup>1</sup>Analysis Group, Inc., Boston, MA, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>3</sup>Analysis Group, Inc., New York, NY, USA
- PCN16 A14 pgA192 COMPARATIVE EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION AGAINST CERVICAL ABNORMALITIES BY DOSE LEVEL IN A COHORT OF PRIVATELY-INSURED U.S. GIRLS**  
Bensimon AG<sup>1</sup>, Hernan MA<sup>2</sup>, Gibson T<sup>3</sup>, Fung V<sup>3</sup>, Chernew M<sup>3</sup>, Landrum MB<sup>4</sup>, Newhouse JP<sup>4</sup>, Schuster M<sup>3</sup>, Hsu J<sup>5</sup>,<sup>1</sup>Harvard University, Cambridge, MA, USA, <sup>2</sup>Harvard T. H. Chan School of Public Health, Boston, MA,

USA, <sup>3</sup>Harvard Medical School, Boston, MA, USA, <sup>4</sup>Harvard University, Boston, MA, USA, <sup>5</sup>Associate Professor of Medicine, Boston, MA, USA

- PCN17 A15 pgA192 PREDICTING PHASE III SURVIVAL OUTCOMES USING PHASE II TRIAL DATA IN NSCLC AND RCC**  
**Macaulay R**, Tan H, PAREXEL, London, UK
- PCN18 A16 pgA192 URSODEOXYCHOLIC AND CHENODEOXYCHOLIC ACID EXERT DISTINCT CYTOTOXIC EFFECTS ON COLON CANCER CELLS**  
**Pavlovic N**<sup>1</sup>, Stankov K<sup>2</sup>, Stanimirov B<sup>1</sup>, Stojancevic M<sup>1</sup>, Kojic V<sup>3</sup>, Bogdanovic G<sup>3</sup>, Mikov M<sup>1</sup>, <sup>1</sup>Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro, <sup>2</sup>Clinical Center of Vojvodina, Novi Sad, Serbia and Montenegro, <sup>3</sup>Oncology Institute of Vojvodina, Novi Sad, Serbia and Montenegro
- PCN19 A17 pgA192 COMPARING THE EFFICACY OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SRES): A CRITICAL APPRAISAL OF THREE PIVOTAL TRIALS**  
**Strite S**<sup>1</sup>, Stuart ME<sup>2</sup>, Beckman V<sup>3</sup>, Öhrling K<sup>3</sup>, <sup>1</sup>Delfini Group, LLC, Portland, OR, USA, <sup>2</sup>Delfini Group, LLC/UW School of Medicine, Seattle, WA, USA, <sup>3</sup>Amgen Inc., Thousand Oaks, CA, USA
- PCN20 A18 pgA193 IS METFORMIN EXPOSURE ASSOCIATED WITH IMPROVED SURVIVAL IN HEAD AND NECK CANCER PATIENTS? A LARGE POPULATION-BASED COHORT STUDY**  
**Alcuský M J**<sup>1</sup>, Keith S<sup>1</sup>, Karagiannis TS<sup>2</sup>, Rabinowitz C<sup>1</sup>, Louis D<sup>1</sup>, Maio V<sup>1</sup>, <sup>1</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- PCN21 A19 pgA193 IDENTIFICATION AND CHARACTERIZATION OF LONG TERM SURVIVAL POPULATION IN NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES**  
**Luaces P**<sup>1</sup>, Sanchez L<sup>1</sup>, Viada C<sup>1</sup>, Rodriguez PC<sup>1</sup>, Alvarez M<sup>1</sup>, Fonte C<sup>2</sup>, Muchene L<sup>3</sup>, Shkedy S<sup>3</sup>, Lage A<sup>1</sup>, <sup>1</sup>Center of Molecular Immunology, Havana, Cuba, <sup>2</sup>Havana University, La Habana, Cuba, <sup>3</sup>Hasselt University, Hasselt, Belgium
- PCN22 A20 pgA193 PRALATREXATE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS**  
**Yang Y**<sup>1</sup>, Hsu YE<sup>2</sup>, Chiu H<sup>3</sup>, Chen Y<sup>1</sup>, Hsieh C<sup>4</sup>, Lin W<sup>5</sup>, <sup>1</sup>National Taiwan University, Taipei, Taiwan, <sup>2</sup>Taipei Medical University, Taipei, Taiwan, <sup>3</sup>Chinese Medical University, Taichung, Taiwan, <sup>4</sup>Oriental Institute of Technology, New Taipei City, Taiwan, <sup>5</sup>Chang Jung Christian University, Tainan, Taiwan
- PCN23 A21 pgA193 HETEROGENEITY OF TREATMENT EFFECT OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH INCIDENT METASTATIC PROSTATE CANCER**  
**Aly A**<sup>1</sup>, Hussain A<sup>2</sup>, Mullins CD<sup>3</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>University of Maryland School of Medicine, Baltimore, MD, USA, <sup>3</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA
- PCN24 B1 pgA193 NUCLEOSIDE ANALOGUES, STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION**  
**Tsan Y**<sup>1</sup>, Lin M<sup>2</sup>, Ho W<sup>2</sup>, Chen P<sup>3</sup>, <sup>1</sup>Taichung Veterans General Hospital, Taichung, Taiwan, <sup>2</sup>Department of Public Health, China Medical University, Taichung, Taiwan, <sup>3</sup>Department of Public Health, National Taiwan University College of Public Health, Taipei, Taiwan
- PCN25 B2 pgA193 INCIDENCE AND PREVALENCE OF BASAL CELL CARCINOMA IN A LARGE UNITED STATES COMMERCIALY INSURED POPULATION**  
Goldenberg G<sup>1</sup>, **Karagiannis TS**<sup>2</sup>, Palmer JB<sup>2</sup>, Lotya J<sup>3</sup>, O'Neill CB<sup>3</sup>, Kisa RM<sup>2</sup>, Herrera V<sup>2</sup>, <sup>1</sup>Mount Sinai School of Medicine, New York, NY, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>3</sup>Novartis Ireland Ltd, Elm Park, Ireland
- PCN26 B3 pgA194 EPIDEMIOLOGY AND TREATMENT OF RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN THE EU5**  
Nersesyan K<sup>1</sup>, Robinson D<sup>1</sup>, Wolfe G<sup>1</sup>, Pelletier C<sup>2</sup>, Forsythe A<sup>2</sup>, **Pomerantz D**<sup>1</sup>, <sup>1</sup>Kantar Health, Horsham, PA, USA, <sup>2</sup>Eisai, Woodcliff Lake, NJ, USA
- PCN27 B4 pgA194 BONE PAIN, SKELETAL RELATED EVENTS AND OPIOID USE IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES**  
**Valderrama A**<sup>1</sup>, Eapen S<sup>2</sup>, Hennessey KA<sup>3</sup>, Jones C<sup>4</sup>, Wen L<sup>1</sup>, Germino J<sup>5</sup>, Duh MS<sup>3</sup>, <sup>1</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, <sup>2</sup>Analysis Group (at the time of study), Boston, MA, USA, <sup>3</sup>Analysis Group, Boston, MA, USA, <sup>4</sup>Analysis Group, In, Boston, MA, USA, <sup>5</sup>Bayer Healthcare, Whippany, NJ, USA
- PCN28 B5 pgA194 PRE-EXISTING TYPE 2 DIABETES MELLITUS AND 5-YEAR MORTALITY AMONG ELDERLY MEDICARE BENEFICIARIES WITH COLORECTAL CANCER**  
**Goyat R**, Madhavan SS, Bose S, Sambamoorthi U, West Virginia University, Morgantown, WV, USA
- PCN30 B6 pgA194 SHORT- AND LONG-TERM SURVIVAL ASSOCIATED WITH LAPAROSCOPIC VERSUS OPEN COLECTOMY IN EARLY-STAGE COLON CANCER: FINDINGS FROM A RETROSPECTIVE COHORT STUDY**  
**Goyal RK**, Davis KL, RTI Health Solutions, Research Triangle Park, NC, USA
- PCN31 B7 pgA194 OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER TREATED WITH 1ST-LINE ENDOCRINE THERAPY VS. CHEMOTHERAPY**  
**Vekeman F**<sup>1</sup>, Hao Y<sup>2</sup>, Cheng WY<sup>3</sup>, Fortier J<sup>4</sup>, Robitaille M<sup>5</sup>, Duh MS<sup>3</sup>, <sup>1</sup>Groupe d'analyse, Montreal, QC, Canada, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>3</sup>Analysis Group, Boston, MA,

- USA, <sup>4</sup>Groupe d'analyse, Ltée, Montreal, QC, Canada, <sup>5</sup>Groupe d'analyse, Itée, Montreal, QC, Canada
- PCN32 B8** *pgA195* **ADJUSTING OVERALL SURVIVAL ESTIMATES FOR TREATMENT SWITCHING: A CASE STUDY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER**  
**Naidoo S**<sup>1</sup>, Ivanescu C<sup>2</sup>, Skaltsa K<sup>3</sup>, Phung D<sup>4</sup>, Holmstrom S<sup>5</sup>, Latimer N<sup>6</sup>, <sup>1</sup>Astellas Pharma Europe, Ltd, Chertsey, UK, <sup>2</sup>Quintiles, Hoofddorp, The Netherlands, <sup>3</sup>Quintiles Consulting, Barcelona, Spain, <sup>4</sup>Astellas Pharma Europe, Leiden, The Netherlands, <sup>5</sup>Astellas Pharma Europe BV, Leiden, The Netherlands, <sup>6</sup>University of Sheffield, Sheffield, UK
- PCN33 B9** *pgA195* **CONDITIONAL SURVIVAL PROBABILITIES FOR PREVIOUSLY UNTREATED ADVANCED MELANOMA PATIENTS RECEIVING IPILIMUMAB: MODEL BASED ANALYSIS**  
Lee D<sup>1</sup>, **Kotapati S**<sup>2</sup>, Porter J<sup>1</sup>, Hertel N<sup>3</sup>, Zagorska A<sup>4</sup>, Hatswell AJ<sup>1</sup>, <sup>1</sup>BresMed, Sheffield, UK, <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA, <sup>3</sup>Bristol Myers Squibb, Uxbridge, UK, <sup>4</sup>Bristol-Myers Squibb, Rueil Malmaison, France

---

### CANCER - Cost Studies

- PCN34 B10** *pgA195* **EXAMINING THE BUDGET IMPACT OF ADOPTING NETUPITANT/PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN A U.S. HEALTH PLAN**  
**Knoth RL**<sup>1</sup>, Abouzaid S<sup>1</sup>, Faria C<sup>2</sup>, Powers A<sup>1</sup>, <sup>1</sup>Eisai, Inc., Woodcliff Lake, NJ, USA, <sup>2</sup>Formerly Eisai, Inc., Woodcliff Lake, NJ, USA
- PCN35 B11** *pgA195* **LUNG CANCER ECONOMIC BURDEN FROM A PRIVATE HEALTHCARE SYSTEM PERSPECTIVE IN BRAZIL**  
**Ferreira CN**<sup>1</sup>, Santana CF<sup>1</sup>, Paloni Ed<sup>2</sup>, Campi Fd<sup>2</sup>, Rufino CS<sup>1</sup>, <sup>1</sup>Pfizer Brasil, São Paulo, Brazil, <sup>2</sup>Orizon, Barueri, Brazil
- PCN36 B12** *pgA195* **THE UTILIZATION OF LAPAROSCOPIC VERSUS OPEN LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA OR SECONDARY COLORECTAL METASTASES: A BUDGET IMPACT ANALYSIS**  
**Ondrejicka DA**, Goldstein LJ, Johnson and Johnson Medical Companies, Markham, ON, Canada
- PCN37 B13** *pgA195* **ECONOMIC IMPACT OF THE ADDITION OF AXITINIB AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN THE ECUATORIAN PUBLIC HEALTHCARE SECTOR**  
Rosado-Buzzo A<sup>1</sup>, **Albuja M**<sup>2</sup>, Garcia-Molliendo L<sup>3</sup>, Luna-Casas G<sup>3</sup>, <sup>1</sup>Links and Links, Mexico City, Mexico, <sup>2</sup>Pfizer Ecuador, Quito, Mexico, <sup>3</sup>Links and links, Mexico City, Mexico
- PCN38 B14** *pgA196* **BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A U.S. PAYER PERSPECTIVE**  
**Bui CN**<sup>1</sup>, O'Day K<sup>2</sup>, Flanders S<sup>1</sup>, Oestreicher N<sup>3</sup>, Francis P<sup>3</sup>, Posta L<sup>1</sup>, Popelar B<sup>2</sup>, Tang H<sup>1</sup>, Balk M<sup>3</sup>, <sup>1</sup>Astellas Scientific and Medical Affairs, Northbrook, IL, USA, <sup>2</sup>Xcenda, Palm Harbor, FL, USA, <sup>3</sup>Medivation Inc, San Francisco, CA, USA
- PCN39 B15** *pgA196* **MODELING ANNUAL PROJECTED REVENUE IMPACT OF THERAPY INTRODUCTION FOR PATIENTS WITH BRAF V600 METASTATIC MELANOMA FROM A HOSPITAL PERSPECTIVE**  
Cinfio FN<sup>1</sup>, Bly CA<sup>1</sup>, Perk S<sup>1</sup>, Smolen LJ<sup>2</sup>, **Day MA**<sup>1</sup>, Klein RW<sup>1</sup>, <sup>1</sup>Medical Decision Modeling, Indianapolis, IN, USA, <sup>2</sup>Medical Decision Modeling Inc., Indianapolis, IN, USA
- PCN40 B16** *pgA196* **UNIVERSAL VERSUS TARGETED SCREENING OF COLON CANCERS FOR LYNCH SYNDROME: COST AND DIAGNOSTIC EFFECTIVENESS ANALYSES BASED ON CLINICAL EXPERIENCE**  
**Erten MZ**<sup>1</sup>, Fernandez LP<sup>2</sup>, Zenali M<sup>1</sup>, McKinnon W<sup>3</sup>, Koliiba C<sup>2</sup>, Jones C<sup>1</sup>, Greenblatt M<sup>1</sup>, <sup>1</sup>University of Vermont - College of Medicine, Burlington, VT, USA, <sup>2</sup>University of Vermont, Burlington, VT, USA, <sup>3</sup>University of Vermont Cancer Center, Burlington, VT, USA
- PCN41 B17** *pgA196* **HOSPITAL CANCER BURDEN IN ARGENTINA: COSTS, MORTALITY AND READMISSIONS**  
**Insua J**, Hospital Universitario Austral, Pacheco, Argentina
- PCN42 B18** *pgA196* **TREATMENT PATTERNS AND COSTS ASSOCIATED WITH SUNITINIB AND PAZOPANIB TREATMENT FOR RENAL CELL CARCINOMA: A COMMERCIAL HEALTH CLAIMS ANALYSIS**  
**Harnett J**, MacLean E, Bhattacharyya H, Cisar L, Hoang CJ, Mardekian J, Pfizer, Inc., New York, NY, USA
- PCN43 B19** *pgA197* **A COST COMPARISON OF SPLIT-DOSE REDUCED-VOLUME ORAL SULFATE SOLUTION (OSS) AND POLYETHYLENE GLYCOL WITH ELECTROLYTES SOLUTION (PEG-ELS)**  
Cleveland M<sup>1</sup>, Yermakov S<sup>2</sup>, Davis M<sup>2</sup>, Campbell R<sup>2</sup>, **Huynh L**<sup>2</sup>, Farraye F<sup>3</sup>, Yenikomshian M<sup>2</sup>, <sup>1</sup>Braintree Laboratories, Braintree, MA, USA, <sup>2</sup>Analysis Group, Inc., Boston, MA, USA, <sup>3</sup>Boston Medical Center, Boston University School of Medicine, Boston, MA, USA
- PCN44 B20** *pgA197* **THE COSTS OF CANCER-RELATED ABSENTEEISM: A SYSTEMATIC REVIEW OF THE LITERATURE**  
**Yu JS**<sup>1</sup>, Seal B<sup>2</sup>, Carlson JJ<sup>1</sup>, <sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
- PCN45 B21** *pgA197* **COST COMPARISON OF FIRST LINE METASTATIC RENAL CELL CARCINOMA TREATMENTS USING A RETROSPECTIVE CLAIMS DATASET**  
**Margolis J**<sup>1</sup>, Princic N<sup>2</sup>, Doan J<sup>3</sup>, Lenhart G<sup>2</sup>, Motzer R<sup>4</sup>, <sup>1</sup>Truven Health Analytics, Bala Cynwyd, PA, USA, <sup>2</sup>Truven Health Analytics, Cambridge, MA, USA, <sup>3</sup>Bristol-Myers Squibb, Wallingford, CT, USA, <sup>4</sup>Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, USA

- PCN46 C1** *pgA197* **CHOICE OF SEQUENTIAL BIOLOGICAL THERAPIES IN METASTATIC COLORECTAL CANCER (MCRC): A COST COMPARISON ANALYSIS FOR WILD-TYPE KRAS MCRC PATIENTS IN BRAZIL**  
**Tsuchiya CT**, Kim HS, La Scala CS, Roche Brazil, São Paulo, Brazil
- PCN47 C2** *pgA197* **HEALTHCARE RESOURCE UTILIZATION AND MEDICAL CARE COST ASSOCIATED WITH NEW BIO-SURGICAL HEMOSTASIS IN CHINA**  
**Ma Y<sup>1</sup>**, Gu X<sup>2</sup>, Wu J<sup>3</sup>, Yue N<sup>4</sup>, Lyu R<sup>4</sup>, <sup>1</sup>China Health Insurance Research Association, Beijing, China, <sup>2</sup>Dalian Medical University, Dalian, China, <sup>3</sup>Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, <sup>4</sup>Johnson & Johnson Medical Device, Beijing, China
- PCN48 C3** *pgA198* **SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION**  
**Lachaine J<sup>1</sup>**, Lachance S<sup>2</sup>, Lambert-Obry V<sup>1</sup>, Bibeau J<sup>1</sup>, <sup>1</sup>University of Montreal, Montreal, QC, Canada, <sup>2</sup>Maisonneuve-Rosemont Hospital, Montreal, QC, Canada
- PCN49 C4** *pgA198* **ESTIMATION OF DIRECT HEALTHCARE COSTS OF GYNECOLOGIC CANCER IN THE U.S.: AN ANALYSIS OF 2007-2011 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA**  
**Park C**, Lawson KA, The University of Texas at Austin, Austin, TX, USA
- PCN50 C5** *pgA198* **HOSPITAL UTILIZATION IN PATIENTS WITH EBSTEIN'S ANOMALY**  
Craver CW<sup>1</sup>, **Belk K<sup>2</sup>**, <sup>1</sup>MedAssets, Inc., Huntersville, NC, USA, <sup>2</sup>MedAssets, Mooresville, NC, USA
- PCN51 C6** *pgA198* **HEALTH CARE UTILIZATION AND COST ASSOCIATED WITH RADIOIODINE REFRACTORY (RAI-R) DIFFERENTIATED THYROID CANCER (DTC)**  
**Abouzaid S<sup>1</sup>**, Li X<sup>1</sup>, Rietschel P<sup>2</sup>, <sup>1</sup>Eisai, Inc., Woodcliff Lake, NJ, USA, <sup>2</sup>Eisai, Inc, Woodcliff Lake, NJ, USA
- PCN52 C7** *pgA198* **COSTS OF TREATING SKELETAL-RELATED EVENTS AMONG PROSTATE CANCER PATIENTS WITH BONE METASTASES IN A COMMERCIAL INSURED POPULATION IN THE US**  
**Zhong Y<sup>1</sup>**, Yao J<sup>2</sup>, Donga P<sup>3</sup>, Bilir SP<sup>4</sup>, Valderrama A<sup>5</sup>, <sup>1</sup>Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA, <sup>2</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, <sup>3</sup>IMS Health, Plymouth Meeting, PA, USA, <sup>4</sup>IMS Health, San Francisco, CA, USA, <sup>5</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
- PCN53 C8** *pgA198* **SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF PANCREATIC CANCER**  
**Aggarwal S<sup>1</sup>**, Topaloglu H<sup>1</sup>, Kumar S<sup>2</sup>, <sup>1</sup>NOVEL Health Strategies, Chevy Chase, MD, USA, <sup>2</sup>GLOBAL ACCESS Monitor, Bethesda, MD, USA
- PCN54 C9** *pgA199* **SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF CUTANEOUS T-CELL LYMPHOMA**  
**Aggarwal S**, Topaloglu H, NOVEL Health Strategies, Chevy Chase, MD, USA
- PCN55 C10** *pgA199* **RATES, TIMING, AND COSTS OF SHORT-TERM DISABILITY (STD) AND LONG-TERM DISABILITY (LTD) IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED MELANOMA**  
Hallmeyer S<sup>1</sup>, Gilloteau I<sup>2</sup>, Limone B<sup>3</sup>, Johnson W<sup>3</sup>, **Malangone-Monaco E<sup>3</sup>**, <sup>1</sup>Oncology Specialists SC, Park Ridge, IL, USA, <sup>2</sup>Bristol-Myers Squibb, Lawrenceville, NJ, USA, <sup>3</sup>Truven Health Analytics, New York, NY, USA
- PCN56 C11** *pgA199* **REVIEW OF DISEASE BURDEN OF LUNG CANCER IN CHINA'S BEIJING AND SHANGHAI**  
**HU C<sup>1</sup>**, Huang L<sup>2</sup>, Zhao D<sup>2</sup>, Xu L<sup>2</sup>, <sup>1</sup>Astrazeneca(China), Beijing, China, <sup>2</sup>Astrazeneca (China), Beijing, China
- PCN57 C12** *pgA199* **ACCESS OF ORAL CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC) IN FIRST LINE TREATMENT IN BRAZIL: IMPACT TO THE PATTERNS OF CARE AND COST OF ILLNESS**  
**Piedade A<sup>1</sup>**, Goes L<sup>2</sup>, Minowa E<sup>1</sup>, Castro AP<sup>1</sup>, Alves AF<sup>1</sup>, <sup>1</sup>Evidências - Kantar Health, Campinas, Brazil, <sup>2</sup>Evidências - Kantar Health, Campinas, Brazil
- PCN58 C13** *pgA199* **HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH MULTIPLE SWITCHING OF TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA**  
Kropf P<sup>1</sup>, **Barnes G<sup>2</sup>**, Tang B<sup>2</sup>, Pathak A<sup>2</sup>, Issa J<sup>3</sup>, <sup>1</sup>Fox Chase Cancer Center, Philadelphia, PA, USA, <sup>2</sup>Teva Pharmaceutical, Frazer, PA, USA, <sup>3</sup>Temple University School of Medicine, Philadelphia, PA, USA
- PCN59 C14** *pgA199* **DIRECT MEDICAL COSTS OF HER2 POSITIVE BREAST CANCER MANAGEMENT IN IRAN: A CLAIMS DATABASE AND DATA MINING ANALYSIS**  
**AnsariPour A<sup>1</sup>**, ZendeDel K<sup>2</sup>, Uyl - de Groot CA<sup>1</sup>, NaemiSanatDost A<sup>3</sup>, Redekop WK<sup>1</sup>, <sup>1</sup>Erasmus University Rotterdam, Rotterdam, The Netherlands, <sup>2</sup>Tehran Medical Sciences and Medical education University, Tehran, Iran, <sup>3</sup>Independent researcher, Virginia Beach, SC, USA
- PCN60 C15** *pgA200* **A COST-EFFECTIVENESS ANALYSIS OF A BIOMARKER TEST COMPARED TO STANDARD OF CARE SURVEILLANCE IN PATIENTS WITH BARRETT'S ESOPHAGUS**  
**Bock JA<sup>1</sup>**, Pitcavage J<sup>1</sup>, Snyder S<sup>1</sup>, Critchley-Thorne R<sup>2</sup>, <sup>1</sup>Geisinger Health System, Danville, PA, USA, <sup>2</sup>Cernostics Inc., Pittsburgh, PA, USA
- PCN61 C16** *pgA200* **ASSESSING THE ECONOMIC BURDEN OF U.S. MEDICARE PATIENTS DIAGNOSED WITH NON-HODGKIN'S LYMPHOMA**  
**Xie L<sup>1</sup>**, Keshishian A<sup>1</sup>, Du J<sup>1</sup>, Baser O<sup>2</sup>, <sup>1</sup>STATinMED Research, Ann Arbor, MI, USA, <sup>2</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA
- PCN62 D1** *pgA200* **ASSESSING THE ECONOMIC BURDEN AND HEALTH CARE RESOURCE UTILIZATIONS OF U.S. MEDICARE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS**

Xie L<sup>1</sup>, Keshishian A<sup>1</sup>, Du J<sup>1</sup>, Baser O<sup>2</sup>,<sup>1</sup>STATinMED Research, Ann Arbor, MI, USA, <sup>2</sup>STATinMED Research, The University of Michigan, MEF University, Ann Arbor, MI, USA

**PCN63 D2 pgA200 SYSTEMATIC LITERATURE REVIEW OF COST OF ADVERSE EVENTS IN CANCER TREATMENTS IN THE US**

Gala S, Nanavaty M, Market Access Solutions LLC, Raritan, NJ, USA

**PCN64 D3 pgA200 PERCEPTIONS OF BIOSIMILAR MONOCLONAL ANTIBODIES AMONGST EU5 BUDGET HOLDERS**

Gardiner RB, Access Partnership, London, UK

**PCN65 D4 pgA201 THE CLINICAL AND ECONOMIC BURDEN OF POST-THORACOTOMY PAIN SYNDROME (PTPS) AFTER LUNG RESECTION SURGERY: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA**

Ghosh SK<sup>1</sup>, Roy S<sup>2</sup>, Akerman E<sup>3</sup>, DeVenezia R<sup>3</sup>, Yoo A<sup>3</sup>, Li G<sup>3</sup>, Fegelman E<sup>1</sup>,<sup>1</sup>Johnson & Johnson (Ethicon), Cincinnati, OH, USA, <sup>2</sup>Ethicon, Somerville, NJ, USA, <sup>3</sup>Johnson & Johnson, New Brunswick, NJ, USA

**PCN66 D5 pgA201 THE CLINICAL AND ECONOMIC BURDEN OF SIGNIFICANT BLEEDING DURING LUNG RESECTION SURGERY: A RETROSPECTIVE MATCHED COHORT ANALYSIS OF REAL-WORLD DATA**

Ghosh SK<sup>1</sup>, Roy S<sup>2</sup>, Daskiran M<sup>3</sup>, Levine R<sup>3</sup>, Yoo A<sup>3</sup>, Li G<sup>3</sup>, Fegelman E<sup>1</sup>,<sup>1</sup>Johnson & Johnson (Ethicon), Cincinnati, OH, USA, <sup>2</sup>Ethicon, Somerville, NJ, USA, <sup>3</sup>Johnson & Johnson, New Brunswick, NJ, USA

**PCN67 D6 pgA201 EVALUATING THE COST OF TREATING BLADDER CANCER WITH AND WITHOUT METASTASES**

Seal B<sup>1</sup>, Shermock KM<sup>2</sup>, Asche CV<sup>3</sup>, Chang J<sup>1</sup>, Kreilick C<sup>1</sup>, Yao J<sup>1</sup>, Cameron J<sup>1</sup>, Morland K<sup>4</sup>, Zagadailov EA<sup>4</sup>, Eaddy M<sup>4</sup>,<sup>1</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, <sup>2</sup>The Johns Hopkins Medical Institutions, Baltimore, MD, USA, <sup>3</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>4</sup>Xcenda, Palm Harbor, FL, USA

**PCN68 D7 pgA201 COST OF CARE FOR GASTRIC CANCER IN PATIENTS WITH AND WITHOUT METASTASES**

Shermock KM<sup>1</sup>, Asche CV<sup>2</sup>, Seal B<sup>3</sup>, Kreilick C<sup>3</sup>, Chang J<sup>3</sup>, Zagadailov EA<sup>4</sup>, Kish J<sup>4</sup>, Eaddy M<sup>4</sup>, Xia F<sup>3</sup>,<sup>1</sup>The Johns Hopkins Medical Institutions, Baltimore, MD, USA, <sup>2</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>3</sup>Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, <sup>4</sup>Xcenda, Palm Harbor, FL, USA

**PCN69 D8 pgA201 COST OF TREATMENT OF RADIOPHARMACEUTICAL AND CHEMOTHERAPY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES IN HOSPITAL SETTING**

Wen L<sup>1</sup>, Valderrama A<sup>1</sup>, Carlton R<sup>2</sup>, Eaddy M<sup>2</sup>, Seal B<sup>1</sup>,<sup>1</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, <sup>2</sup>Xcenda, Palm Harbor, FL, USA

**PCN70 D9 pgA201 COST – EFFICACY STUDY FOR IPILIMUMAB IN THE CHILEAN MARKET**

Rovegno M<sup>1</sup>, Llanos C<sup>2</sup>, Galleguillos S<sup>2</sup>, Garrido Lecca S<sup>3</sup>,<sup>1</sup>Departamento de Medicina Intensiva, Facultad de Medicina, Universidad Católica de Chile., Santiago, Chile, <sup>2</sup>IAS, Facultad de Economía y Negocios, Universidad de Chile, Santiago, Chile, <sup>3</sup>Bristol-Myers Squibb, Lima, Peru

**PCN71 D10 pgA202 BEVACIZUMAB FOR FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER PATIENTS WITH HIGH RISK OF RELAPSE: A COST EFFECTIVE OPTION FOR CANADIAN PATIENTS**

Ghatage P<sup>1</sup>, Wright EJ<sup>2</sup>, Martin Nunez I<sup>2</sup>, Yin L<sup>2</sup>, Ray J<sup>3</sup>,<sup>1</sup>University of Calgary, Calgary, AB, Canada, <sup>2</sup>Hoffmann-La Roche, Mississauga, ON, Canada, <sup>3</sup>F. Hoffmann-La Roche, Basel, Switzerland

**PCN72 D11 pgA202 INDIRECT COSTS AMONG METASTATIC BREAST CANCER PATIENTS RECEIVING ERIBULIN**

Wan Y<sup>1</sup>, Copher R<sup>2</sup>, Corman S<sup>1</sup>, Abouzaid S<sup>2</sup>, Gao X<sup>1</sup>,<sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Eisai, Inc., Woodcliff Lake, NJ, USA

**PCN73 D12 pgA202 COST-EFFECTIVENESS ANALYSIS OF ARSENIC TRIOXIDE FOR THE TREATMENT OF IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA**

Tallman M<sup>1</sup>, Lo-Coco F<sup>2</sup>, Barnes G<sup>3</sup>, Kruse M<sup>4</sup>, Wildner R<sup>4</sup>, Martin M<sup>5</sup>, Mueller U<sup>6</sup>, Tang B<sup>3</sup>, Pathak A<sup>3</sup>, Weinstein MC<sup>7</sup>,<sup>1</sup>Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA, <sup>2</sup>University Tor Vergata, Rome, Italy, <sup>3</sup>Teva Pharmaceutical, Frazer, PA, USA, <sup>4</sup>Optum, Waltham, MA, USA, <sup>5</sup>MAPI, Uxbridge, UK, <sup>6</sup>Teva Pharmaceutical, Ehrenkirchen, Germany, <sup>7</sup>Harvard T. H. Chan School of Public Health, Boston, MA, USA

**PCN74 D13 pgA202 COST-EFFECTIVENESS OF RADIUM-223 DICHLORIDE (RADIUM-223) IN ALSYMPCA: A COST-EFFECTIVENESS ANALYSIS OF RADIUM-223+BEST STANDARD OF CARE (BSOC) COMPARED WITH PLACEBO+BSOC IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES IN CANADA**

Henricks P<sup>1</sup>, Cislo P<sup>2</sup>, Zhan L<sup>2</sup>, Beaudet A<sup>3</sup>, Grabbi E<sup>4</sup>, Lloyd A<sup>4</sup>, Fleshner N<sup>5</sup>, Chin W<sup>6</sup>,<sup>1</sup>Bayer Inc, Toronto, ON, Canada, <sup>2</sup>Bayer HealthCare, Whippany, NJ, USA, <sup>3</sup>IMS Health, Basel, Switzerland, <sup>4</sup>IMS Health, London, UK, <sup>5</sup>Princess Margaret Hospital, University Health Network, Toronto, ON, Canada, <sup>6</sup>ILEX Consulting, Toronto, ON, Canada

**PCN75 D14 pgA202 COST-EFFECTIVENESS ANALYSIS OF FEMALE HUMAN PAPILLOMAVIRUS VACCINATION IN MAINLAND CHINA**

Gai R, National Center of Child Health and Development, Tokyo, Japan

**PCN77 D15 pgA203 USE OF ABIRATERONE IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A REAL-LIFE COST-EFFECTIVENESS STUDY**

Rocha J, Vanhuysse M, Aprikian A, Cury F, Kassouf W, Dragomir A, McGill University Health Centre, Montreal,

QC, Canada

- PCN78 D16 pgA203 COST EFFECTIVENESS ANALYSIS OF ERIBULIN MESYLATE AS A TREATMENT FOR METASTATIC BREAST CANCER IN SPAIN: MANAGEMENT IN THE LATER LINES OF THERAPY**  
**Majethia U**<sup>1</sup>, Tremblay G<sup>2</sup>, Kontoudis I<sup>3</sup>, DeRosendo J<sup>4</sup>,<sup>1</sup>Eisai Inc., Woodcliff Lake, NJ, USA, <sup>2</sup>Eisai, Woodcliff Lake, NJ, USA, <sup>3</sup>Eisai Europe Ltd., Hatfield,, UK, <sup>4</sup>Eisai Farmacéutica, S.A., Madrid, Spain
- PCN79 E1 pgA203 IDELALISIB PLUS RITUXIMAB VERSUS PLACEBO PLUS RITUXIMAB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: A COST-EFFECTIVENESS ANALYSIS**  
**Yu JS**<sup>1</sup>, Seal B<sup>2</sup>, Carlson JJ<sup>1</sup>,<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA
- PCN80 E2 pgA203 COST-EFFECTIVENESS OF EML4-ALK GENE TARGETED FIRST-LINE CERITINIB TREATMENT AMONG PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER**  
**Upadhyay N**, Atreja N,<sup>1</sup>University of Houston, Houston, TX, USA
- PCN81 E3 pgA203 COST-EFFECTIVENESS OF SORAFENIB FOR TREATMENT OF RADIOACTIVE IODINE (RAI)-REFRACTORY LOCALLY ADVANCED/METASTATIC DIFFERENTIATED THYROID CANCER (DTC) IN TURKEY**  
Erdal E<sup>1</sup>, Sayman H<sup>2</sup>, Turkmen C<sup>3</sup>, Aral F<sup>3</sup>, Yildiz O<sup>4</sup>, Okutur K<sup>5</sup>, Parali E<sup>1</sup>, **Deger C**<sup>1</sup>, Tunalioglu A<sup>1</sup>, Sar C<sup>1</sup>, Asan S<sup>1</sup>, Sumer F<sup>1</sup>, Ozel O<sup>1</sup>,<sup>1</sup>Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, <sup>2</sup>Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, <sup>3</sup>Istanbul University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, <sup>4</sup>Medipol University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, <sup>5</sup>Acibadem University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey
- PCN82 E4 pgA307 ECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT**  
**Huicochea-Bartelt JL**<sup>1</sup>, Burbano X<sup>2</sup>, Palacios E<sup>2</sup>, Herran S<sup>1</sup>, Valencia C<sup>1</sup>,<sup>1</sup>Boehringer Ingelheim, Distrito Federal, Mexico, <sup>2</sup>Guia Mark, Distrito Federal, Mexico
- PCN84 E5 pgA204 COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VS LIPEGFILGRASTIM TO REDUCE THE INCIDENCE OF FEBRILE NEUTROPENIA IN PATIENTS WITH EARLY STAGE BREAST CANCER OR NON-HODGKIN LYMPHOMA**  
**Fust K**<sup>1</sup>, Li X<sup>2</sup>, Maschio M<sup>3</sup>, Villa G<sup>4</sup>, Parthan A<sup>5</sup>, Barron R<sup>6</sup>, Weinstein MC<sup>7</sup>, Somers L<sup>8</sup>, Hoefkens C<sup>9</sup>, Lyman GH<sup>10</sup>,<sup>1</sup>OptumInsight, Waltham, MA, USA, <sup>2</sup>Amgen Inc., Thousand Oaks, CA, USA, <sup>3</sup>OptumInsight, Burlington, ON, Canada, <sup>4</sup>Amgen (Europe) GmbH, Zug, Switzerland, <sup>5</sup>OptumInsight, Cambridge, MA, USA, <sup>6</sup>Amgen, Inc., Thousand Oaks, CA, USA, <sup>7</sup>Harvard T. H. Chan School of Public Health, Boston, MA, USA, <sup>8</sup>OncoLogX, Antwerp, Belgium, <sup>9</sup>Amgen Belgium, Brussels, Belgium, <sup>10</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- PCN85 E6 pgA204 COST-EFFECTIVENESS OF TREATING ADVANCED PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOR PATIENTS WITH EVEROLIMUS VERSUS SUNITINIB IN SWEDEN**  
**Perrin A**<sup>1</sup>, Park J<sup>2</sup>, Jacob J<sup>3</sup>, Welin S<sup>4</sup>,<sup>1</sup>LA-SER Analytica, New York, NY, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>3</sup>Novartis Sverige AB, Täby, Sweden, <sup>4</sup>Akademiska sjukhuset/Uppsala University Hospital, Uppsala, Sweden
- PCN86 E7 pgA204 COST-EFFECTIVENESS OF CETUXIMAB+FOLFIRI VERSUS BEVACIZUMAB+FOLFIRI AT THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL – THE FIRE 3 TRIAL ECONOMIC PERSPECTIVE**  
**Junqueira M**<sup>1</sup>, de Campos MC<sup>1</sup>, Cardoso AP<sup>1</sup>, von Hohnhorst P<sup>2</sup>, Fujii RK<sup>1</sup>,<sup>1</sup>Merck Serono, São Paulo, Brazil, <sup>2</sup>Merck Serono, Frankfurt, Germany
- PCN87 E8 pgA204 COST-EFFECTIVENESS OF MULTIPLEXED PREDICTIVE BIOMARKER SCREENING IN NON-SMALL CELL LUNG CANCER**  
**Romanus D**<sup>1</sup>, Cardarella S<sup>2</sup>, Cutler D<sup>1</sup>, Landrum MB<sup>1</sup>, Lindeman N<sup>3</sup>, Gazelle GS<sup>4</sup>,<sup>1</sup>Harvard University, Boston, MA, USA, <sup>2</sup>Dana-Farber Cancer Institute, Boston, MA, USA, <sup>3</sup>Brigham and Women's Hospital, Boston, MA, USA, <sup>4</sup>Massachusetts General Hospital, Boston, MA, USA
- PCN88 E9 pgA205 COMPARING TYROSINE KINASE INHIBITOR TREATMENT STRATEGIES FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE WHEN IMATINIB LOSES PATENT EXCLUSIVITY IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS**  
**Padula W**<sup>1</sup>, Larson R<sup>1</sup>, Conti R<sup>1</sup>, Dusetzina S<sup>2</sup>,<sup>1</sup>University of Chicago, Chicago, IL, USA, <sup>2</sup>University of North Carolina, Chapel Hill, NC, USA
- PCN89 E10 pgA205 COST-EFFECTIVENESS ANALYSIS OF ADO-TRASTUZUMAB EMTANSINE COMPARED TO LAPATINIB-CAPECITABINE COMBINATION IN HER2-POSITIVE METASTATIC BREAST CANCER**  
**Gor D**, Lee W, Kim K, Mohan A, Peng K, Sarangpur S, Shinde S, Touchette D,<sup>1</sup>University of Illinois at Chicago, Chicago, IL, USA
- PCN90 E11 pgA205 COST-EFFECTIVENESS OF A BIOPSY-BASED 8-PROTEIN PROGNOSTIC ASSAY TO OPTIMIZE TREATMENT DECISIONS IN GLEASON 3+3 AND 3+4 PROSTATE CANCER**  
**Roth JA**<sup>1</sup>, Ramsey S<sup>1</sup>, Carlson JJ<sup>2</sup>,<sup>1</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA, <sup>2</sup>University of Washington, Seattle, WA, USA

- PCN92 E12 pgA205 COST EFFECTIVENESS ANALYSIS OF PANITUMUMAB + FOLFOX AS 1ST LINE OF TREATMENT OF MCRC RAS-WT**  
Alva ME<sup>1</sup>, Vargas J<sup>2</sup>,<sup>1</sup>Amgen, Mexico City, Mexico, <sup>2</sup>Econopharma, Mexico City, Mexico
- PCN93 E13 pgA205 COST-EFFECTIVENESS OF CETUXIMAB+FOLFIRI VERSUS FOLFIRI AT THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL – THE CRYSTAL TRIAL RAS SUBGROUP ECONOMIC PERSPECTIVE**  
Junqueira M<sup>1</sup>, de Campos MC<sup>1</sup>, Cardoso AP<sup>1</sup>, von Hohnhorst P<sup>2</sup>, Fujii RK<sup>1</sup>,<sup>1</sup>Merck Serono, São Paulo, Brazil, <sup>2</sup>Merck Serono, Frankfurt, Germany
- PCN94 E14 pgA205 ECONOMIC EVALUATION OF TRANSARTERIAL CHEMOEMBOLIZATION WITH LIPIODOL VERSUS DRUG ELUTING BEAD FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS**  
Fouad S<sup>1</sup>, Elsisi G<sup>1</sup>, Elmahdawy M<sup>2</sup>,<sup>1</sup>Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt, Cairo, Egypt, <sup>2</sup>Hospital Pharmacy Administration Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt, Cairo, Egypt
- PCN95 E15 pgA206 COST-EFFICACY ANALYSIS OF IPILUMUMAB IN PERU**  
Garrido Lecca S<sup>1</sup>, Donato BM<sup>2</sup>, Juarez-Garcia A<sup>3</sup>,<sup>1</sup>Bristol-Myers Squibb, Lima, Peru, <sup>2</sup>Bristol-Myers Squibb Company, Wallingford, CT, USA, <sup>3</sup>Bristol-Myers Squibb Company, Mexico City, Mexico
- PCN96 E16 pgA206 LONG-TERM OUTCOMES OF HPV VACCINATION IN PREVENTION OF ANAL CANCER IN OLDER HIV-POSITIVE MEN WHO HAVE SEX WITH MEN**  
Deshmukh AA<sup>1</sup>, Chhatwal J<sup>1</sup>, Chiao EY<sup>2</sup>, Nyitray AG<sup>3</sup>, Das P<sup>1</sup>, Cantor SB<sup>1</sup>,<sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, TX, USA, <sup>2</sup>Baylor College of Medicine, Houston, TX, USA, <sup>3</sup>The University of Texas School of Public Health, Houston, TX, USA
- PCN97 F1 pgA206 CASE STUDIES OF COST-EFFECTIVENESS FOR CO-ADMINISTERED BRANDED ONCOLOGY PRODUCTS: PREDICTIONS FROM AN EARLY ECONOMIC MODEL**  
Smith NJ<sup>1</sup>, Cordina G<sup>1</sup>, Cheynel J<sup>2</sup>, Blissett D<sup>2</sup>, Beckerman R<sup>1</sup>,<sup>1</sup>CBPartners, New York, NY, USA, <sup>2</sup>CBPartners, London, UK
- PCN98 F2 pgA206 COST-EFFECTIVENESS OF CO-ADMINISTERED BRANDED THERAPIES IN ONCOLOGY: PRICING INSIGHTS FROM AN EARLY ECONOMIC MODEL**  
Smith NJ<sup>1</sup>, Cordina G<sup>1</sup>, Cheynel J<sup>2</sup>, Blissett D<sup>2</sup>, Beckerman R<sup>1</sup>,<sup>1</sup>CBPartners, New York, NY, USA, <sup>2</sup>CBPartners, London, UK
- PCN100 F3 pgA206 A NEW APPROACH FOR IDENTIFICATION OF DISEASE-RELATED MEDICAL BILLING CODES FOR CHRONIC LYMPHOCYTIC LEUKEMIA FOR USE IN COST ANALYSES IN ADMINISTRATIVE CLAIMS DATA**  
Kozma C<sup>1</sup>, Slaton T<sup>2</sup>, Paris A<sup>3</sup>, Ellis L<sup>4</sup>,<sup>1</sup>C-K Consulting, St. Helena Island, SC, USA, <sup>2</sup>C-K Consulting, West Columbia, SC, USA, <sup>3</sup>Vigilytics, Victor, NY, USA, <sup>4</sup>Janssen Scientific Affairs, LLC, Horsham, PA, USA
- PCN101 F4 pgA206 HOSPITAL UTILIZATION IN PATIENTS WITH MANTLE CELL LYMPHOMA**  
Belk K<sup>1</sup>, Craver CW<sup>2</sup>,<sup>1</sup>MedAssets, Mooresville, NC, USA, <sup>2</sup>MedAssets, Inc., Huntersville, NC, USA
- PCN102 F5 pgA207 ASSESSING THE BURDEN OF ILLNESS AND HOSPITAL UTILIZATION OF POLYCEMIA VERA**  
Belk K<sup>1</sup>, Craver C<sup>2</sup>,<sup>1</sup>MedAssets, Mooresville, NC, USA, <sup>2</sup>MedAssets, Huntersville, NC, USA
- PCN103 F6 pgA207 TIME AND MOTION STUDY FOR RITUXIMAB SC VS IV IN COLOMBIAN PATIENTS WITH NON-HODGKIN LYMPHOMA**  
Saenz Ariza SA,<sup>1</sup>Productos Roche, Bogota, Colombia
- PCN104 F7 pgA207 VALUING SURVIVAL GAINS IN MYELODYSPLASTIC SYNDROMES ATTRIBUTABLE TO NOVEL CANCER THERAPIES**  
MacEwan JP<sup>1</sup>, Yin W<sup>2</sup>, Khan ZM<sup>3</sup>, Kaura S<sup>3</sup>,<sup>1</sup>Precision Health Economics, Los Angeles, CA, USA, <sup>2</sup>University of California Los Angeles, Los Angeles, CA, USA, <sup>3</sup>Celgene Corporation, Summit, NJ, USA

---

### CANCER - Patient-Reported Outcomes & Patient Preference Studies

- PCN105 F8 pgA207 ADHERENCE TO TAMOXIFEN AND ARMOATASE INHIBITORS AMONG WOMEN ENROLLED IN MEDICAID PROGRAM**  
Khanna R, Joshi N, Pace P, Banahan III B,<sup>1</sup>University of Mississippi, University, MS, USA
- PCN106 F9 pgA207 THE EFFECTIVENESS OF CAREPAK® ADHERENCE PACKAGING IN INCREASING LENALIDOMIDE THERAPY DURATION**  
Rice G, Nolan R, Grigorian M,<sup>1</sup>Diplomat Specialty Pharmacy, Flint, MI, USA
- PCN107 F10 pgA208 MEASURING RISK FACTORS FOR NON-ADHERENCE USING PATIENT-REPORTED OUTCOMES IN STUDIES EVALUATING ADHERENCE WITH ORAL ANTINEOPLASTIC AGENTS: A 10-YEAR REVIEW**  
Mokiou S<sup>1</sup>, Hanson KA<sup>2</sup>,<sup>1</sup>UBC: An Express Scripts Company, London, UK, <sup>2</sup>UBC: An Express Scripts Company, Dorval, QC, Canada
- PCN108 F11 pgA208 MEASUREMENT OF HEALTH STATE UTILITIES FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA BY USING TIME TRADE-OFF AND VISUAL ANALOG SCALE METHOD**  
Kang HN, Choi I, Song H, Park S, Suh D,<sup>1</sup>Chung-Ang University, Seoul, South Korea
- PCN109 F12 pgA208 UTILITIES FOR HEALTH STATES IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AND FACTORS INFLUENCING UTILITY VALUES**



Choi I, **Park S**, Song J, Jun JH, Suh D, Chung-Ang University, Seoul, South Korea

- PCN110 F13** *pgA208* **MAPPING UTILITY SCORES FROM EUROPEAN ORGANIZATION FOR TREATMENT OF CANCER CORE-30 QUESTIONNAIRE SCORES (EORTC QLQ-C30) IN RELAPSED MULTIPLE MYELOMA**  
**Ashaye AO**<sup>1</sup>, Zhang J<sup>1</sup>, Bender RH<sup>2</sup>, Altincatal A<sup>1</sup>, Panjabi S<sup>3</sup>,<sup>1</sup>Evidera, Lexington, MA, USA, <sup>2</sup>Evidera, Bethesda, MD, USA, <sup>3</sup>Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA
- PCN111 F14** *pgA208* **EVAUATION OF CORCORDANCE BETWEEN PATIENT REPORTED OUTCOMES (PROS) AND CLINICIAN REPORTED OUTCOMES (CROS) IN PATIENTS WITH METASTATIC BRAIN DISEASE**  
Taychakhoonavudh S<sup>1</sup>, **Lal L**<sup>2</sup>, Swint J<sup>3</sup>,<sup>1</sup>Chulalongkorn University, Bangkok, Thailand, <sup>2</sup>Cardinal Health, Missouri City, TX, USA, <sup>3</sup>University of Texas School of Public Health, Houston, TX, USA
- PCN112 F15** *pgA208* **USING FACT DATA TO PREDICT PREFERENCE-BASED UTILITY MEASURES FOR PEOPLE WITH MALIGNANT MELANOMA: A REVIEW OF THE EVIDENCE**  
Ara R<sup>1</sup>, Paisley S<sup>1</sup>, Robinson AA<sup>1</sup>, Azough A<sup>2</sup>, **Mensah L**<sup>2</sup>,<sup>1</sup>The University of Sheffield, Sheffield, UK, <sup>2</sup>Amgen Ltd, Uxbridge, UK
- PCN113 F16** *pgA209* **PATIENT ACCESS TO CANCER CARE EXCELLENCE (PACE) SOUTH KOREA SURVEY**  
**Lee E**<sup>1</sup>, Kim Y<sup>2</sup>, Ramers-Verhoeven C<sup>3</sup>, Lee S<sup>4</sup>, Lee S<sup>4</sup>, Bae M<sup>4</sup>, Rajan N<sup>5</sup>, Orlando M<sup>6</sup>, Kim J<sup>4</sup>,<sup>1</sup>College of Pharmacy, Sungkyunkwan University, Suwon, South Korea, <sup>2</sup>College of Medicine, Korea University, Seoul, South Korea, <sup>3</sup>Eli Lilly, Houten, The Netherlands, <sup>4</sup>Eli Lilly, Seoul, South Korea, <sup>5</sup>Eli Lilly, West Ryde, Australia, <sup>6</sup>Eli Lilly, Buenos Aires, Argentina
- PCN114 G1** *pgA209* **QUALITATIVE METHODS FOR ASSESSING PATIENT, CAREGIVER, AND PHYSICIAN-REPORTED EXPERIENCES WITH ORAL MEDICATIONS FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC)**  
**Hazel-Fernandez LA**<sup>1</sup>, Uribe C<sup>1</sup>, Flanders S<sup>2</sup>, Suehs B<sup>1</sup>, Dye T<sup>3</sup>,<sup>1</sup>Comprehensive Health Insights, Louisville, KY, USA, <sup>2</sup>Astellas Scientific and Medical Affairs, Northbrook, IL, USA, <sup>3</sup>University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
- PCN115 G2** *pgA209* **PATIENT PREFERENCES FOR PALLIATIVE TREATMENT OF LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER AND ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION: A CHOICE-BASED CONJOINT ANALYSIS STUDY FROM GERMANY**  
Hofheinz R<sup>1</sup>, Clouth J<sup>2</sup>, Borchardt-Wagner J<sup>2</sup>, Wagner U<sup>2</sup>, Weidling E<sup>2</sup>, Jen M<sup>3</sup>, **Brueck P**<sup>2</sup>,<sup>1</sup>University Hospital Mannheim, Mannheim, Germany, <sup>2</sup>Lilly Deutschland GmbH, Bad Homburg, Germany, <sup>3</sup>Eli Lilly and Company, Surrey, UK
- PCN116 G3** *pgA209* **PARTICIPATION IN CERVICAL CANCER SCREENING AND KNOWLEDGE ON HUMAN PAPILLOMAVIRUS AMONG WOMEN IN VÁC, HUNGARY**  
**Vajda R**<sup>1</sup>, Miskolczi A<sup>2</sup>, Horváthné Kívés Z<sup>1</sup>, Pakai A<sup>2</sup>, Gyuró M<sup>1</sup>, Molics B<sup>1</sup>, Csákvári T<sup>2</sup>, Répásy B<sup>1</sup>, Danku N<sup>1</sup>, Boncz I<sup>1</sup>,<sup>1</sup>University of Pécs, Pécs, Hungary, <sup>2</sup>University of Pécs, Zalaegerszeg, Hungary
- PCN117 G4** *pgA209* **INCLUSION OF PATIENT-REPORTED OUTCOME MEASURES IN REGISTERED CLINICAL TRIALS: EVIDENCE FROM CLINICALTRIALS.GOV (2007-2013)**  
**Vodicka E**<sup>1</sup>, Kim K<sup>1</sup>, Devine B<sup>1</sup>, Gnanasakthy A<sup>2</sup>, Scoggins J<sup>3</sup>, Patrick DL<sup>1</sup>,<sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>RTI Health Solutions, Research Triangle Park, NC, USA, <sup>3</sup>IMPAQ International, LLC, Columbia, MD, USA
- PCN118 G5** *pgA210* **TASTE DYSFUNCTION AFTER HEAD AND NECK CANCER TREATMENT: A META-ANALYSIS**  
**McLaughlin LA**, Saint Louis University, St. Louis, MO, USA
- PCN119 G6** *pgA210* **THE EMERGING ROLE OF PATIENT-REPORTED OUTCOMES (PROS) IN FDA HEMATOLOGY AND ONCOLOGY PRODUCT LABELS**  
Tse J, **Shingler SL**, Nixon A, PRMA Consulting, Hampshire, UK
- PCN120 G7** *pgA210* **DEVELOPMENT AND CONTENT VALIDITY TESTING OF THE PATIENT-REPORTED OUTCOMES OF FATIGUE IN CANCER (PROOF-C) SYMPTOM SEVERITY ASSESSMENT (SSA)**  
**Yaworsky A**<sup>1</sup>, Ojo O<sup>1</sup>, Foley C<sup>1</sup>, Bonthapally V<sup>2</sup>, Ma E<sup>2</sup>, Norquist J<sup>3</sup>, Pompilus F<sup>1</sup>, Pearson J<sup>3</sup>, Park J<sup>4</sup>, Arbuckle R<sup>5</sup>,<sup>1</sup>Adelphi Values Boston, Boston, MA, USA, <sup>2</sup>Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, <sup>3</sup>Merck & Co Whitehouse Station, Whitehouse Station, NJ, USA, <sup>4</sup>Alcon Laboratories, Inc., Fort Worth, TX, USA, <sup>5</sup>Adelphi Values Ltd., Bollington, UK
- PCN121 G8** *pgA210* **PATIENT-REPORTED OUTCOMES (PROS) IN BLADDER CANCER**  
**Barsdorf AI**<sup>1</sup>, Pease S<sup>2</sup>,<sup>1</sup>Pfizer, Inc., New York, NY, USA, <sup>2</sup>Pfizer, New York, NY, USA
- PCN122 G9** *pgA210* **PATIENT-REPORTED OUTCOMES (PROS) IN OVARIAN CANCER CLINICAL TRIALS**  
**Pease S**, Barsdorf AI, Pfizer, New York, NY, USA
- PCN123 G10** *pgA210* **DOES THE GENERIC CANCER OUTCOME MEASURE EORTC QLQ-C30 WORK IN MYELOFIBROSIS?**  
Mukuria CW, Brazier J, **Rafia R**, University of Sheffield, Sheffield, UK
- PCN124 G11** *pgA211* **DERIVATION OF A PREFERENCE-BASED MEASURE FOR METASTATIC BREAST CANCER USING THE EORTC QLQ-30 AND QLQ-BR 23**  
**Hudgens S**<sup>1</sup>, Lloyd A<sup>2</sup>, Campbell P<sup>1</sup>, Harrington A<sup>1</sup>, Forsythe A<sup>3</sup>,<sup>1</sup>Clinical Outcomes Solutions, Tucson, AZ, USA, <sup>2</sup>Bladon Associates Ltd, Oxford, UK, <sup>3</sup>Eisai, Woodcliff Lake, NJ, USA

- PCN125 G12** *pgA211* **IMPACT OF ENZALUTAMIDE OR ABIRATERONE ACETATE + PREDNISONE (AbP) ON QUALITY OF LIFE (QoL) IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) THAT HAS PROGRESSED ON OR AFTER DOXETAXEL: A COMPARATIVE EFFECTIVENESS STUDY**  
 Cella D<sup>1</sup>, Ivanescu C<sup>2</sup>, Phung D<sup>3</sup>, Mansbach H<sup>4</sup>, Holmstrom S<sup>5</sup>, **Naidoo S**<sup>6,1</sup>, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, <sup>2</sup>Quintiles, Hoofddorp, The Netherlands, <sup>3</sup>Astellas Pharma Europe, Leiden, The Netherlands, <sup>4</sup>Medivation, Inc, San Francisco, CA, USA, <sup>5</sup>Astellas Pharma Europe BV, Leiden, The Netherlands, <sup>6</sup>Astellas Pharma EMEA, Chertsey, UK
- PCN126 G13** *pgA211* **HEALTH-RELATED QUALITY OF LIFE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CRITICAL LITERATURE REVIEW**  
 Nussbaum N<sup>1</sup>, Dorff T<sup>2</sup>, Abernethy A<sup>1</sup>, Dolan C<sup>3</sup>, **Flanders S**<sup>4</sup>, Oestreicher N<sup>5</sup>, George DJ<sup>1</sup>, <sup>1</sup>Duke University Hospital, Durham, NC, USA, <sup>2</sup>Keck Medicine of USC, Los Angeles, CA, USA, <sup>3</sup>CMD Consulting, Inc., Sandy, UT, USA, <sup>4</sup>Astellas Scientific and Medical Affairs, Northbrook, IL, USA, <sup>5</sup>Medivation Inc, San Francisco, CA, USA
- PCN127 G14** *pgA211* **EXPLORATORY PSYCHOMETRIC ANALYSIS OF THE EQ-5D IN A MYELOFIBROSIS POPULATION**  
**Rafia R**, Mukuria CW, University of Sheffield, Sheffield, UK
- PCN128 G15** *pgA211* **QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION**  
**Hayran M**, Yüce D, Hüseyin B, Esin E, Kilickap S, Erman M, Celik I, Hacettepe University Cancer Institute, Ankara, Turkey
- PCN129 G16** *pgA212* **ELICITATION OF HEALTH-RELATED QUALITY-OF-LIFE CONCEPTS ASSOCIATED WITH TRIPLE-NEGATIVE BREAST CANCER**  
**Holmstrom S**<sup>1</sup>, Hawken NA<sup>2</sup>, Dam S<sup>3</sup>, Aballea S<sup>4</sup>, Oestreicher N<sup>5</sup>, Evans C<sup>6</sup>, Novak A<sup>7</sup>, Dydo M<sup>8</sup>, <sup>1</sup>Astellas Pharma Europe BV, Leiden, The Netherlands, <sup>2</sup>Creativ-Ceutical, Luxembourg, Luxembourg, <sup>3</sup>Creativ-Ceutical, Copenhagen, Denmark, <sup>4</sup>Creativ-Ceutical, Paris, France, <sup>5</sup>Medivation Inc, San Francisco, CA, USA, <sup>6</sup>Endpoint Outcomes, Boston, MA, USA, <sup>7</sup>Astellas Pharma Global Development, Leiden, The Netherlands, <sup>8</sup>Astellas Pharma Global Development, Northbrook, IL, USA
- PCN130 G17** *pgA212* **INVARIANCE OF QUALITY OF LIFE QUESTIONNAIRE EORTC QLQC30 IN DIFFERENT CANCER INDICATIONS**  
**Viada C**<sup>1</sup>, Ballesteros J<sup>2</sup>, Fors M<sup>3</sup>, Luaces P<sup>1</sup>, Sanchez L<sup>1</sup>, Alvarez M<sup>1</sup>, Frias A<sup>1</sup>, Crombet T<sup>1</sup>, <sup>1</sup>Center of Molecular Immunology, Havana, Cuba, <sup>2</sup>University of the Basque Country, Leioa, Cuba, <sup>3</sup>National Center of Clinical Trials, Havana, Cuba

---

## CANCER - Health Care Use & Policy Studies

- PCN131 G18** *pgA212* **PATIENTS' GROUPS AND ADVOCACY IN ONCOLOGY: AWARENESS, SUPPORT AND UNMET NEEDS**  
**Holtz L**<sup>1</sup>, Minowa E<sup>2</sup>, Julian G<sup>3</sup>, <sup>1</sup>Oncoguia, São Paulo, Brazil, <sup>2</sup>Evidências - Kantar Health, Campinas, Brazil, <sup>3</sup>Evidências - Kantar Health, São Paulo, Brazil
- PCN132 G19** *pgA212* **INFLUENCE OF PATIENT-REPORTED OUTCOMES ON MARKET ACCESS DECISIONS IN DECENTRALIZED MARKETS (BRAZIL, ITALY, SPAIN, AND THE UNITED STATES)**  
**Hogue S**<sup>1</sup>, Brogan AP<sup>1</sup>, DeMuro C<sup>1</sup>, Barrett A<sup>1</sup>, D'Alessio D<sup>2</sup>, Bal V<sup>2</sup>, <sup>1</sup>RTI Health Solutions, Research Triangle Park, NC, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
- PCN134 G20** *pgA212* **THE DISCONNECT BETWEEN FUNDING DECISIONS OF CANCER DRUGS AND COMPANION DIAGNOSTIC TESTS IN CANADA**  
**Poinas A**, Wyatt G, Wyatt Health Management, Oakville, ON, Canada
- PCN135 G21** *pgA212* **ARE BIOMARKERS A BIG MARKET ACCESS BONUS? US AND EU5 PAYER PERSPECTIVES AND PRESCRIBING PATTERNS FOR KEY TARGETED NON-SMALL-CELL LUNG CANCER AGENTS**  
**Cox J**<sup>1</sup>, Roberts D<sup>1</sup>, Gheorghe D<sup>1</sup>, Moore R<sup>2</sup>, <sup>1</sup>Decision Resources Group, London, UK, <sup>2</sup>Decision Resources Group, Nashville, TN, USA
- PCN136 H1** *pgA213* **CHARACTERIZATION OF TEMOZOLOMIDE UTILIZATION IN GLIOBLASTOMA**  
**Hill K**<sup>1</sup>, Jiang S<sup>2</sup>, Patel D<sup>2</sup>, Worthington K<sup>1</sup>, <sup>1</sup>Celldex Therapeutics, Hampton, NJ, USA, <sup>2</sup>Pharmerit International, Bethesda, MD, USA
- PCN137 H2** *pgA213* **METASTATIC MELANOMA PATIENT CHARACTERISTICS AS A DETERMINING FACTOR FOR BRAF GENE MUTATION TESTING AND TREATMENT IN CANADA – A RETROSPECTIVE COHORT STUDY**  
**Djokic S**<sup>1</sup>, Lapierre M<sup>2</sup>, <sup>1</sup>IMS Health, Ottawa, ON, Canada, <sup>2</sup>IMS Health, Kirkland, QC, Canada
- PCN138 H3** *pgA213* **BURDEN OF SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS: A SYSTEMATIC LITERATURE REVIEW**  
**Mehta S**<sup>1</sup>, Cooke C<sup>1</sup>, Gao X<sup>1</sup>, Labotka R<sup>2</sup>, Berg D<sup>2</sup>, Parameswaran H<sup>3</sup>, Lin HM<sup>2</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, <sup>3</sup>Medical College of Wisconsin, Milwaukee, WI, USA
- PCN139 H4** *pgA213* **THE IMPACT OF ENDOSCOPIC LINEAR STAPLING DEVICE STABILITY IN THORACIC SURGERY: A DELPHI PANEL APPROACH**  
 Miller D<sup>1</sup>, Gonzalez Rivas D<sup>2</sup>, **Meyer K**<sup>3</sup>, Clark RS<sup>4</sup>, Kohno T<sup>5</sup>, <sup>1</sup>WellStar Medical Group, Austell, GA, USA, <sup>2</sup>Coruña University Hospital, Coruna, Spain, <sup>3</sup>Xcenda Corporation, Tampa, FL, USA, <sup>4</sup>Xcenda, Palm Harbor, FL, USA, <sup>5</sup>Toranomon Hospital, Tokyo, Japan
- PCN140 H5** *pgA213* **THE EXPECTED IMPACT OF ONCOLOGY BIOSIMILARS IN BRAZIL AND MEXICO: PAYERS AND**

## ONCOLOGISTS CONSIDER THE COST-EFFECTIVENESS OF THESE CHEAPER ALTERNATIVES

**Zevallos S**<sup>1</sup>, Ribeiro A<sup>1</sup>, Cox J<sup>2</sup>,<sup>1</sup>Decision Resources Group, Burlington, MA, USA, <sup>2</sup>Decision Resources Group, London, UK

- PCN141 H6** *pgA213* **PROMOTING MARKET ACCESS THROUGH BREAKTHROUGH THERAPY DESIGNATION: CAN THIS ACCOLADE HELP CONVINCING PAYERS AND PRESCRIBERS?**  
**Duval A**, Cox J, Decision Resources Group, London, UK
- PCN142 H7** *pgA214* **OPIOID PRESCRIPTION TRENDS IN THE RURAL US: EVIDENCE FROM THE NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS) DATA 2006-2010**  
**Qureshi Z**<sup>1</sup>, Haider MR<sup>1</sup>, Probst J<sup>2</sup>, Horner R<sup>1</sup>, Bennett C<sup>3</sup>,<sup>1</sup>University of South Carolina, Columbia, SC, USA, <sup>2</sup>University of South Carolina, COLUMBIA, SC, USA, <sup>3</sup>University of South Carolina College of Pharmacy, Columbia, SC, USA
- PCN143 H8** *pgA214* **PCODR – THE POINTLESS CANADIAN ONCOLOGY DRUG REVIEW?**  
**Macaulay R**, Surtel A, PAREXEL, London, UK
- PCN144 H9** *pgA214* **PRIORITY ACCESS FOR THE BIGGEST – VARIABLE PROVINCIAL ACCESS TO ONCOLOGY DRUGS IN CANADA**  
**Macaulay R**, Surtel A, PAREXEL, London, UK
- PCN145 H10** *pgA214* **COMPARING THE VALUE OF A PCODR FULL APPROVAL VERSUS AN APPROVAL CONDITIONAL ON COST-EFFECTIVENESS BEING IMPROVED TO AN ADEQUATE LEVEL**  
**Macaulay R**, Surtel A, PAREXEL, London, UK
- PCN146 H11** *pgA214* **REIMBURSEMENT APPROVAL OF ONCOLOGY DRUGS IN CANADA SUPPORTED BY A DATA PACKAGE LACKING PHASE III TRIAL DATA**  
**Macaulay R**, PAREXEL, London, UK
- PCN147 H12** *pgA215* **THE IMPACT OF ACCESS TO CANCER CARE ON ADJUVANT ENDOCRINE THERAPY USE AMONG BREAST CANCER SURVIVORS IN APPALACHIA**  
**Tan X**<sup>1</sup>, Marshall V<sup>1</sup>, Camacho F<sup>2</sup>, Anderson RT<sup>2</sup>, Balkrishnan R<sup>1</sup>,<sup>1</sup>University of Michigan, Ann Arbor, MI, USA, <sup>2</sup>University of Virginia, Charlottesville, VA, USA
- PCN148 H13** *pgA215* **GENDER-SPECIFIC DIFFERENCES IN RISK FOR COST-RELATED MEDICATION NONADHERENCE AMONG CANCER SURVIVORS**  
**Lee MJ**, Li Y, Khan MM, University of South Carolina, COLUMBIA, SC, USA
- PCN149 H14** *pgA215* **PATTERN OF ADJUNCTIVE DRUG UTILIZATION IN ONCOLOGY DEPARTMENT**  
**Gogineni S**, chalapathi Institute of pharmaceutical Sciences, Guntr, India
- PCN150 H15** *pgA215* **US BURDEN OF ILLNESS ASSOCIATED WITH ADJUVANT THERAPY FOR STAGE I-III MELANOMA**  
Houts AC<sup>1</sup>, **Ward M**<sup>2</sup>, Oglesby A<sup>3</sup>, Walker MS<sup>1</sup>, Saverno K<sup>1</sup>,<sup>1</sup>Vector Oncology, Memphis, TN, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, <sup>3</sup>GlaxoSmithKline, RTP, NC, USA
- PCN152 H16** *pgA215* **HIGH COST ONCOLOGY PRODUCTS DEMAND ADDITIONAL ADMINISTRATIVE BURDEN ON CLINICIANS IN SELECT EMEA MARKETS**  
**Gardiner RB**, Access Partnership, London, UK
- PCN153 H17** *pgA215* **BASELINE CHARACTERISTICS OF PATIENTS PROVIDED CANCER CARE WITHIN A NOVEL COMMERCIAL HEALTH PLAN CANCER CARE QUALITY PROGRAM**  
**Willey V**<sup>1</sup>, Quimbo R<sup>2</sup>, Tunceli O<sup>3</sup>, Mack M<sup>3</sup>, Malin J<sup>4</sup>,<sup>1</sup>HealthCore, Inc, Wilmington, DE, USA, <sup>2</sup>HealthCore Inc., Wilmington, DE, USA, <sup>3</sup>HealthCore, Inc., Wilmington, DE, USA, <sup>4</sup>Anthem, Woodland Hills, CA, USA
- PCN154 H18** *pgA216* **THE IMPACT OF EARLY MEDICARE ADMINISTRATIVE CONTRACTOR IMPLEMENTATION ON THE RECEIPT OF CHEMOTHERAPY AND BIOLOGIC AGENTS BY MEDICARE COLON CANCER BENEFICIARIES WITH METASTATIC DISEASE**  
**Vandigo J**, University of Maryland School of Pharmacy, Baltimore, MD, USA
- PCN155 H19** *pgA216* **THE ACCESS AND THE DIFFUSION OF ONCOLOGY DRUGS IN ALGERIA**  
**Aissaoui A**<sup>1</sup>, Kaddar M<sup>2</sup>, Soualmi R<sup>3</sup>,<sup>1</sup>Paris dauphine University, Paris, France, <sup>2</sup>WHO, Oran, Algeria, <sup>3</sup>University of Algiers, algier, Algeria
- PCN156 H20** *pgA216* **FACTORS AFFECTING TIME REQUIRED FOR PCODR DECISION MAKING**  
**Macaulay R**, Surtel A, PAREXEL, London, UK
- PCN157 H21** *pgA216* **IMPACT OF FEDERAL REGULATION ON ACCESS TO ORAL CHEMOTHERAPY (OC) AND HORMONAL THERAPY (HT) IN THE BRAZILIAN PRIVATE HEALTH SYSTEM (PHS)**  
**Piedade A**, Castro AP, Alves AF, Nishikawa AM, Minowa E, Evidências - Kantar Health, Campinas, Brazil
- PCN158 I1** *pgA216* **DETERMINANTS FOR GUIDELINE APPROPRIATE CARE AMONG ELDERLY WOMEN WITH STAGE I-III BREAST CANCER IN A SEER-MEDICARE POPULATION**  
**LeMasters TJ**, Madhavan SS, Sambamoorthi U, Kelly K, Hazard H, Long D, West Virginia University, Morgantown, WV, USA
- PCN159 I2** *pgA216* **VARIATIONS IN PRIMARY TREATMENT AMONG ELDERLY WOMEN WITH EARLY STAGE BREAST**

**CANCER: ASSOCIATIONS WITH FACTORS RELATED TO OLD AGE AND VULNERABLE SOCIO-DEMOGRAPHICS**

LeMasters TJ, Madhavan SS, Sambamoorthi U, Kelly K, Hazard H, Long D, West Virginia University, Morgantown, WV, USA

- PCN160 I3** pgA217 **PAYERS' VIEWS ON HETEROGENEITY OF TREATMENT EFFECT IN ONCOLOGY**  
Aly A<sup>1</sup>, Mullins CD<sup>2</sup>, Pharmerit International, Bethesda, MD, USA, <sup>2</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA
- PCN161 I4** pgA217 **ACCESS TO A MEDICAL HOME AND ITS IMPACT ON HEALTHCARE UTILIZATION AND MEDICAL EXPENDITURE AMONGST CANCER SURVIVORS**  
Shah AB<sup>1</sup>, Li C<sup>2</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, LITTLE ROCK, AR, USA, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AR, USA
- PCN164 I5** pgA217 **THE IMPACT OF GENOMIC TESTING ON CHEMOTHERAPY USE AND MEDICAL SPENDING IN A COMMERCIALY-INSURED POPULATION OF BREAST CANCER PATIENTS**  
Epstein AJ<sup>1</sup>, Wong Y<sup>2</sup>, Mitra N<sup>1</sup>, Vachani A<sup>1</sup>, Hin S<sup>1</sup>, Yang L<sup>1</sup>, Smith-McLallen A<sup>3</sup>, Armstrong K<sup>4</sup>, Groeneveld PW<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, USA, <sup>2</sup>Temple University Health System, Philadelphia, PA, USA, <sup>3</sup>Independence Blue Cross, Philadelphia, PA, USA, <sup>4</sup>Massachusetts General Hospital, Boston, MA, USA
- PCN165 I6** pgA218 **INNOVATIVE PRICING MECHANISMS FOR THERAPIES FOR ADVANCED CANCERS**  
Wight CG, Tolley K, GalbraithWight Ltd., Polegate, UK
- PCN166 I7** pgA218 **THE EVOLVING GLOBAL ROLE OF NONTRADITIONAL PAYERS AND REINSURANCE IN THE REIMBURSEMENT OF HIGH COST THERAPIES**  
Paul A<sup>1</sup>, Spinner DS<sup>2</sup>, Kristopik J<sup>1</sup>, Doyle JJ<sup>3</sup>, Faulkner E<sup>1</sup>, <sup>1</sup>Quintiles Consulting, Durham, NC, USA, <sup>2</sup>Quintiles, Durham, NC, USA, <sup>3</sup>Quintiles, Hawthorne, NY, USA
- PCN167 I8** pgA218 **PERCEPTION OF VALUE OF NEW CANCER DRUGS: A SURVEY OF ONCOLOGISTS IN THE UNITED STATES (US)**  
Narayanan S, Ipsos Healthcare, Columbia, MD, USA
- PCN168 I9** pgA218 **AMERICANS' CANCER INFORMATION (CI) SEEKING EXPERIENCES AND SELF-EFFICACY (SE) IN SEEKING CANCER INFORMATION (CI): A CHARACTERISTIC SNAPSHOT USING 2012-13 HEALTH INFORMATION NATIONAL TRENDS SURVEY (HINTS)**  
Bhandari NR, Hwang M, ST. JOHN'S UNIVERSITY, Jamaica, NY, USA
- PCN169 I10** pgA218 **AN ANALYSIS OF ONCOLOGY DRUG FINANCING IN HONG KONG**  
Sun D, Dutttagupta S, CBPartners, New York, NY, USA
- PCN171 I11** pgA218 **COMPARISON OF EXPECTED HEALTH IMPACTS FOR MAJOR CANCERS: INTEGRATION OF INCIDENCE RATE AND LOSS OF QUALITY-ADJUSTED LIFE EXPECTANCY**  
Hung M<sup>1</sup>, Lai W<sup>2</sup>, Chen HH<sup>3</sup>, Su W<sup>4</sup>, Wang J<sup>1</sup>, <sup>1</sup>Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan, <sup>2</sup>Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, <sup>3</sup>Department of Radiation Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, <sup>4</sup>Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
- PCN172 I12** pgA219 **QUALITY OF EVIDENCE SUPPORTING INCLUSION OF PHARMACOGENOMIC BIOMARKERS IN PRODUCT LABELS OF FDA APPROVED ONCOLOGY THERAPIES**  
Jha RK, Gupta J, Kapoor A, Mazumder D, Optum Global Solutions, Noida, India
- PCN173 I13** pgA219 **CARBOHYDRATE INTAKE AND BREAST CANCER RISK IN AFRICAN AMERICAN AND EUROPEAN AMERICAN WOMEN IN THE WOMEN'S CIRCLE OF HEALTH STUDY**  
Johnson NM<sup>1</sup>, Bandera E<sup>2</sup>, <sup>1</sup>ICON PLC, Morristown, NJ, USA, <sup>2</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
- PCN174 I14** pgA219 **IMMUNE CHECKPOINT INHIBITORS AS ADJUVANTS: FUTURE CHALLENGES FOR PRICING AND REIMBURSEMENT**  
Wieffer HM, McKendrick J, Petropoulos A, Saltman D, PRMA Consulting, Fleet, UK
- PCN175 J1** pgA219 **PREDICTORS OF A POSITIVE CANCER DRUG FUND DECISION**  
Jaksa A, Liden D, Ho Y, Context Matters, New York, NY, USA
- PCN176 J2** pgA219 **BARBEC(EU)D ONCOLOGY MARKET ACCESS – HOW BBQ PULLED PORK IS SIMILAR TO EUROPEAN P&R NEGOTIATIONS**  
Swilling N, Altier J, Simon-Kucher and Partners, Cambridge, MA, USA
- PCN177 J3** pgA220 **IMPACT OF TOLERABILITY PROFILES ON HTA DECISION MAKING IN ONCOLOGY**  
Kreeftmeijer J<sup>1</sup>, Ryan J<sup>2</sup>, Van Engen A<sup>1</sup>, Heemstra L<sup>1</sup>, <sup>1</sup>Quintiles Consulting, Hoofddorp, The Netherlands, <sup>2</sup>AstraZeneca, Cheshire, The Netherlands
- PCN179 J4** pgA220 **HIERARCHY OF CLINICAL ENDPOINTS IN HTA DECISION MAKING IN ONCOLOGY**  
Kreeftmeijer J<sup>1</sup>, Ryan J<sup>2</sup>, Van Engen A<sup>1</sup>, Heemstra L<sup>1</sup>, <sup>1</sup>Quintiles Consulting, Hoofddorp, The

- Netherlands, <sup>2</sup>AstraZeneca, Cheshire, The Netherlands
- PCN180 J5** *pgA220* **IS THERE AN IMPACT OF THE ORPHAN DESIGNATION IN ONCOLOGY ON MARKET ACCESS IN EUROPE?**  
**Boiziau SC**, EMAUD, Claude Bernard Lyon 1 University, Villeurbanne cedex, France
- PCN181 J6** *pgA220* **OPTIMISING MARKET ACCESS OF CANCER DRUGS IN CANADA: A STUDY OF ECONOMIC REVIEWS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW (PCODR) EXPERT COMMITTEE**  
**Qu KQ**<sup>1</sup>, Jiang Y<sup>2</sup>, Gauthier A<sup>2,1</sup>, Amaris, Toronto, ON, Canada, <sup>2</sup>Amaris, London, UK
- PCN182 J7** *pgA220* **USE OF MOLECULAR TESTING PRIOR TO FIRST-LINE ERLOTINIB THERAPY AMONG MEDICARE PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER**  
**Romanus D**<sup>1</sup>, Cutler D<sup>1</sup>, Keating NL<sup>1</sup>, Lennes IT<sup>2</sup>, Lamont E<sup>1</sup>, Gazelle GS<sup>2</sup>, Landrum MB<sup>1,1</sup>, Harvard University, Boston, MA, USA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, USA
- PCN183 J8** *pgA220* **ONCOLOGY DRUGS RECEIVING BREAKTHROUGH THERAPY DESIGNATION: CLINICAL TRIAL CHARACTERISTICS, DRUG PRICING, AND APPROVAL PROCESS**  
**Park Y**<sup>1</sup>, Vegesna A<sup>2</sup>, Ray D<sup>3</sup>, Tsang Y<sup>4,1</sup>, University of Maryland College of Pharmacy, Baltimore, MD, USA, <sup>2</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>3</sup>Rutgers University, Piscataway, NJ, USA, <sup>4</sup>University of Maryland Baltimore, Baltimore, MD, USA
- PCN184 J9** *pgA221* **TREATMENT PATTERNS AMONG ELDERLY METASTATIC COLORECTAL CANCER PATIENTS - A SEER-MEDICARE ANALYSIS**  
**Parikh RC**, Du XL, Morgan RO, Lairson DR, UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, HOUSTON, TX, USA
- PCN186 J10** *pgA221* **CURRENT TREATMENT PATTERNS AND SURVIVAL IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINDINGS FROM A BRIEF SURVEY OF EUROPEAN PHYSICIANS**  
**Davis KL**<sup>1</sup>, Lin HM<sup>2</sup>, Zhang S<sup>3</sup>, Kaye JA<sup>4,1</sup>, RTI Health Solutions, Research Triangle Park, NC, USA, <sup>2</sup>Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, <sup>3</sup>Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, <sup>4</sup>RTI Health Solutions, Waltham, MA, USA
- PCN187 J11** *pgA221* **TREATMENT PATTERNS OF ENDOCRINE THERAPY AND CHEMOTHERAPY AMONG POST-MENOPAUSAL WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER**  
**Lin PL**<sup>1</sup>, Hao Y<sup>2</sup>, Signorovitch JE<sup>1</sup>, Kelley C<sup>1</sup>, Macalalad AR<sup>1</sup>, Ohashi E<sup>1</sup>, Zhou Z<sup>1</sup>, Wu EQ<sup>1,1</sup>, Analysis Group, Inc., Boston, MA, USA, <sup>2</sup>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

---

## GASTROINTESTINAL DISORDERS - Clinical Outcomes Studies

- PGI1 J12** *pgA221* **AN EVALUATION OF CLINICAL REMISSION AND SAFETY AMONG BIOLOGICS FOR MODERATE-TO-SEVERE CROHNS DISEASE: A BAYESIAN NETWORK META-ANALYSIS**  
**Bounthavong M**<sup>1</sup>, Bae YH<sup>2</sup>, Vanness DJ<sup>3</sup>, Kazerooni R<sup>4</sup>, Devine B<sup>5,1</sup>, Univer, SEATTLE, WA, USA, <sup>2</sup>WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA, <sup>3</sup>University of Wisconsin-Madison, Madison, WI, USA, <sup>4</sup>Veterans Affairs San Diego Healthcare System, San Diego, CA, USA, <sup>5</sup>University of Washington, Seattle, WA, USA
- PGI2 J13** *pgA222* **BAYESIAN HIERARCHICAL MODELING OF RANDOMIZED AND NON-RANDOMIZED STUDIES COMPARING CICLOSPORIN WITH IMMEDIATE- AND PROLONGED-RELEASE TACROLIMUS IN LIVER TRANSPLANT RECIPIENTS**  
**Muduma G**<sup>1</sup>, Pollock RF<sup>2</sup>, Odeyemi IA<sup>1</sup>, Saunders R<sup>2,1</sup>, Astellas Pharma EMEA, Chertsey, UK, <sup>2</sup>Ossian Health Economics and Communications GmbH, Basel, Switzerland
- PGI3 J14** *pgA222* **SYSTEMATIC LITERATURE REVIEW, META-ANALYSIS AND INDIRECT TREATMENT COMPARISON OF PROLONGED-RELEASE TACROLIMUS RELATIVE TO CICLOSPORIN AND IMMEDIATE-RELEASE TACROLIMUS AS THE PRIMARY IMMUNOSUPPRESSIVE REGIMEN IN LIVER TRANSPLANT RECIPIENTS**  
**Muduma G**<sup>1</sup>, Saunders R<sup>2</sup>, Odeyemi IA<sup>1</sup>, Pollock RF<sup>2,1</sup>, Astellas Pharma EMEA, Chertsey, UK, <sup>2</sup>Ossian Health Economics and Communications GmbH, Basel, Switzerland
- PGI4 K1** *pgA222* **DUAL VERSUS TRIPLE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI: AN EVIDENCE-BASED META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS**  
**Dasari A**, Gudala K, Bansal D, National Institute of Pharmaceutical Education and Research, Mohali, India
- PGI5 K2** *pgA222* **THE AMELIORATION OF DOXORUBICIN-INDUCED OXIDATIVE LIVER INJURY BY URSODEOXYCHOLIC ACID**  
**Stanimirov B**, Stankov K, Pavlovic N, Stojancevic M, Vukmirovic S, Mikov M, Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro
- PGI6 K3** *pgA222* **14 DAY-SEQUENTIAL, CONCOMITANT, AND HYBRID THERAPIES FOR FIRST-LINE HELICOBACTER PYLORI (H. PYLORI) ERADICATION: A NETWORK META-ANALYSIS**  
**Zhao X**, Wu W, St. John's University, Queens, NY, USA
- PGI7 K4** *pgA222* **META-ANALYSIS OF ULTRASONIC SCALPEL VERSUS ELECTROCAUTERY IN LAPAROSCOPIC CHOLECYSTECTOMY IN CHINA**  
**Yin C**, Metz L, JnJ Medical AP, Singapore, Singapore
- PGI8 K5** *pgA223* **CLINICAL CHARACTERISTICS AND OUTCOMES OF CHRONIC HEPATITIS C (CHC) PATIENTS TREATED**

**WITH NEWER DIRECT-ACTING ANTIVIRAL (DAA)-BASED REGIMENS FROM A LARGE US PAYER PERSPECTIVE**

**Tandon N**<sup>1</sup>, Forlenza J<sup>1</sup>, Goolsby Hunter A<sup>2</sup>, Korror SD<sup>2</sup>, Buikema A<sup>2,1</sup>, Janssen Scientific Affairs, LLC, Titusville, NJ, USA, <sup>2</sup>Optum, Eden Prairie, MN, USA

**PGI9 K6 pgA223 MEASURING THE EFFECTIVENESS OF EARLY INFLIXIMAB USE ON CROHN'S DISEASE HOSPITALIZATIONS USING HIGH-DIMENSIONAL DATA MINING ADJUSTMENT**

**Hutfless S**<sup>1</sup>, Al Kazzi ES<sup>1</sup>, Brant SR<sup>2</sup>, Matos P<sup>3</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, USA, <sup>2</sup>Johns Hopkins University - School of Medicine, Baltimore, MD, USA, <sup>3</sup>Traekos Health Works, Bettendorf, IA, USA

**PGI10 K7 pgA223 TREATMENT OF ACUTE APPENDICITIS IN GERMANY: RESULTS OF THE ANALYSIS OF A HEALTH INSURANCE CLAIMS DATABASE**

**Lange A**<sup>1</sup>, Gosemann J<sup>2</sup>, Zeidler J<sup>1</sup>, Blaser J<sup>3</sup>, Ure BM<sup>2</sup>, Lacher M<sup>2,1</sup>, Leibniz University of Hannover, Hannover, Germany, <sup>2</sup>Hannover Medical School, Hannover, Germany, <sup>3</sup>Techniker Health Insurance, Hannover, Germany

**PGI11 K8 pgA223 ASSOCIATION OF HEPATITIS C VIRUS INFECTION WITH RISK OF CHRONIC KIDNEY DISEASE: SYSTEMATIC REVIEW AND META-ANALYSIS**

**Park H**<sup>1</sup>, Adeyemi A<sup>1</sup>, Henry L<sup>2</sup>, Stepanova M<sup>2</sup>, Younossi Z<sup>3,1</sup>, University of Florida, Gainesville, FL, USA, <sup>2</sup>Betty and Guy Beatty Integrated Center for Research at Inova, Falls Church, VA, USA, <sup>3</sup>Center for Liver Diseases, Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA

**PGI12 K9 pgA223 RISK OF LIVER TRANSPLANT IN TREATED VS. UNTREATED HEPATITIS C**

**Ems D**, Racsa P, Anderson C, Gregory F, Worley K, Humana, Inc., Louisville, KY, USA

---

**GASTROINTESTINAL DISORDERS - Cost Studies**

**PGI13 K10 pgA224 ESTIMATION OF THE BUDGET IMPACT OF RIFAXIMIN TREATMENT IN PATIENTS WITH IRRITABLE BOWEL SYNDROME**

Bozkaya D<sup>1</sup>, Barrett AC<sup>2</sup>, **Migliaccio-Walle K**<sup>1,1</sup>, Xcenda, Palm Harbor, FL, USA, <sup>2</sup>Salix Pharmaceuticals, Inc., Raleigh, NC, USA

**PGI14 K11 pgA224 BUDGET IMPACT ANALYSIS OF HEPATITIS C DRUGS IN MEDICAL**

**Naku F**, Barcelona School of Management-UPF, Brentwood, CA, USA

**PGI15 K12 pgA224 FINANCIAL IMPACTS OF USING OMEPRAZOLE ORAL SUSPENSION FOR PREVENTING UPPER GASTROINTESTINAL BLEEDING EARLY AFTER INTENSIVE CARE ADMISSION**

**Foroutan N**<sup>1</sup>, Foroutan A<sup>2,1</sup>, McMaster University, Hamilton, ON, Canada, <sup>2</sup>Tehran University, Tehran, Iran

**PGI16 K13 pgA224 THE HIGH COST PATIENTS ON WAITING LIST FOR THE LIVER TRANSPLANTATION. MAIN BURDENS AND CONSEQUENCES FOR THE PUBLIC HEALTH SYSTEM**

**Turri JA**, Haddad LB, Andrauss W, D'Albuquerque LA, Diniz MA, Universidade de Sao Paulo, São Paulo, YT, Brazil

**PGI17 K14 pgA224 COST EFFECTIVENESS OF NEW HEPATITIS C THERAPIES**

**Tabano DC**<sup>1</sup>, Dilokthornsakul P<sup>2</sup>, Campbell JD<sup>2</sup>, McQueen RB<sup>2,1</sup>, University of Colorado School of Pharmacy, Aurora, CO, USA, <sup>2</sup>University of Colorado Anschutz Medical Campus, Denver, CO, USA

**PGI18 K15 pgA224 A COST-UTILITY ANALYSIS OF BIOLOGICS FOR MODERATE-TO-SEVERE CROHN'S DISEASE: EVIDENCE SYNTHESIS USING A BAYESIAN NETWORK META-ANALYSIS**

**Bounthavong M**<sup>1</sup>, Bae YH<sup>2</sup>, Devine B<sup>3</sup>, Veenstra DL<sup>3,1</sup>, Univer, SEATTLE, WA, USA, <sup>2</sup>WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA, <sup>3</sup>University of Washington, Seattle, WA, USA

**PGI19 K16 pgA225 HEALTHCARE COSTS OF A CONSECUTIVE COHORT OF PATIENTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE TREATED AT A TERTIARY MEDICAL CENTER IN ISRAEL**

Odes S<sup>1</sup>, Vardi H<sup>1</sup>, Friger M<sup>1</sup>, Schwartz D<sup>2</sup>, Sarid O<sup>1</sup>, Slonim-Nevo V<sup>1</sup>, **Greenberg D**<sup>3,1</sup>, Ben-Gurion University of the Negev, Beer Sheva, Israel, <sup>2</sup>Soroka Medical Center, Beer Sheva, Israel, <sup>3</sup>Ben-Gurion University of the Negev, Beer-Sheva, Israel

**PGI20 K17 pgA225 PREDICTORS OF HIGH HEALTHCARE RESOURCE UTILIZATION AND LIVER DISEASE PROGRESSION AMONG PATIENTS WITH CHRONIC HEPATITIS C**

LaMori J<sup>1</sup>, Tandon N<sup>1</sup>, **Laliberté F**<sup>2</sup>, Germain G<sup>2</sup>, Pilon D<sup>2</sup>, Lefebvre P<sup>2</sup>, Prabhakar A<sup>1,1</sup>, Janssen Scientific Affairs, LLC, Titusville, NJ, USA, <sup>2</sup>Groupe d'analyse, Ltée, Montreal, QC, Canada

**PGI21 K18 pgA225 COST-EFFECTIVENESS OF TREATING HEPATITIS C VIRUS (HCV) GENOTYPE 1 (GT1) PATIENTS WITH ABBVIE 3D (PARITAPREVIR/RITONAVIR/OMBITASVIR AND DASABUVIR ) +/- RIBAVIRIN COMPARED TO HARVONI (SOFOSBUVIR/LEDIPASVIR) IN THE UNITED STATES**

Johnson S<sup>1</sup>, Parise H<sup>1</sup>, Virabhak S<sup>1</sup>, Juday T<sup>2</sup>, Misurski D<sup>3</sup>, Marx SE<sup>2</sup>, **Samp JC**<sup>2,1</sup>, Medicus Economics, LLC, Milton, MA, USA, <sup>2</sup>AbbVie Inc, North Chicago, IL, USA, <sup>3</sup>Abbvie, Chicago, IL, USA

**PGI22 L1 pgA225 ASSESSING THE COST-EFFECTIVENESS OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAM FOR THE PHILIPPINES USING A DYNAMIC TRANSMISSION MODEL**

**Lam HY**<sup>1</sup>, Wu DB<sup>2</sup>, Rivera AS<sup>1</sup>, Alejandria MM<sup>1</sup>, Velasco GN<sup>3</sup>, Sison OT<sup>1</sup>, Ladia MA<sup>1</sup>, Mantaring Jb<sup>1</sup>, Santillan M<sup>1,1</sup>, University of the Philippines Manila, Manila, Philippines, <sup>2</sup>Monash University Malaysia, Subang Jaya, Malaysia, <sup>3</sup>Department of Health Philippines, Manila, Philippines, <sup>4</sup>Philippine Health Insurance Corporation, Pasig

City, Philippines

- PGI23 L2** *pgA225* **COST EFFECTIVENESS OF DACLATASVIR/ASUNAPREVIR VERSUS PEGINTERFERON/RIBAVIRIN AND PROTEASE INHIBITORS FOR THE TREATMENT OF HEPATITIS C GENOTYPE 1B IN CHILE**  
**Vargas C**<sup>1</sup>, Espinoza MA<sup>1</sup>, Giglio A<sup>2</sup>, Soza A<sup>3</sup>,<sup>1</sup>Pontificia Universidad Catolica de Chile, Santiago, Chile, <sup>2</sup>Complejo Asistencial Sótero del Río, Santiago, Chile, <sup>3</sup>Pontificia Universidad Católica de Chile, Santiago, Chile
- PGI24 L3** *pgA226* **COST-EFFECTIVENESS OF INTERFERON-FREE THERAPY FOR HEPATITIS C IN GERMANY - AN APPLICATION OF THE EFFICIENCY FRONTIER APPROACH**  
**Gissel C**<sup>1</sup>, Götz G<sup>1</sup>, Mahlich JC<sup>2</sup>, Repp H<sup>1</sup>,<sup>1</sup>Justus Liebig University, Giessen, Germany, <sup>2</sup>University of Düsseldorf, Düsseldorf, Germany
- PGI25 L4** *pgA226* **LONG-TERM COST PER SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C VIRUS TREATED WITH VIEKIRA PAK +/- RIBAVIRIN AND STANDARD OF CARE IN THE US**  
Virabhak S<sup>1</sup>, Johnson S<sup>1</sup>, Parisé H<sup>1</sup>, Saab S<sup>2</sup>, Juday T<sup>3</sup>, Marx S<sup>3</sup>, Sanchez Y<sup>3</sup>, **Wang A**<sup>3</sup>,<sup>1</sup>Medicus Economics, LLC, Milton, MA, USA, <sup>2</sup>Pflegger Liver Institute, Los Angeles, IL, USA, <sup>3</sup>AbbVie, North Chicago, IL, USA
- PGI26 L5** *pgA226* **USING THE MEDICARE CLAIMS DATABASE TO UNDERSTAND THE ECONOMIC BURDEN OF LIVER DISEASE: A CASE STUDY IN HEPATIC ENCEPHALOPATHY**  
Irish W<sup>1</sup>, Saynisch P<sup>2</sup>, Mallow PJ<sup>3</sup>, Fallon L<sup>3</sup>, **Gunnarsson C**<sup>3</sup>,<sup>1</sup>CTI Clinical Trial and Consulting Services, Raleigh, NC, USA, <sup>2</sup>Harvard University, Cambridge, MA, USA, <sup>3</sup>CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA

---

### GASTROINTESTINAL DISORDERS - Patient-Reported Outcomes & Patient Preference Studies

- PGI27 L6** *pgA226* **PREDICTORS OF HEALTH-RELATED UTILITY WEIGHTS IN A CONSECUTIVE COHORT OF REAL-WORLD CROHN'S DISEASE PATIENTS IN ISRAEL**  
**Greenberg D**<sup>1</sup>, Vardi H<sup>1</sup>, Schwartz D<sup>2</sup>, Friger M<sup>1</sup>, Sarid O<sup>1</sup>, Slonim-Nevo V<sup>1</sup>, Odes S<sup>1</sup>,<sup>1</sup>Ben-Gurion University of the Negev, Beer-Sheva, Israel, <sup>2</sup>Soroka Medical Center, Beer-Sheva, Israel
- PGI28 L7** *pgA226* **PSYCHOMETRIC VALIDATION OF THE DYSPHAGIA SYMPTOM QUESTIONNAIRE IN EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH ORAL BUDESONIDE SUSPENSION**  
**Hudgens S**<sup>1</sup>, Evans C<sup>2</sup>, Philips E<sup>3</sup>, Hill M<sup>3</sup>,<sup>1</sup>Clinical Outcomes Solutions, Tucson, AZ, USA, <sup>2</sup>Endpoint Outcomes, Boston, MA, USA, <sup>3</sup>Meritage Pharma Inc., San Diego, CA, USA
- PGI29 L8** *pgA226* **SELF-REPORTED HEALTH STATUS OF PATIENTS WITH CHRONIC HEPATITIS B IN CHINA**  
**Luo N**<sup>1</sup>, Zhang M<sup>2</sup>, Zhang S<sup>3</sup>, Shang J<sup>4</sup>, Han T<sup>5</sup>, Guo Y<sup>6</sup>, Wang X<sup>7</sup>, Liu J<sup>7</sup>, Bo Q<sup>7</sup>, Wang X<sup>8</sup>, Jia J<sup>9</sup>,<sup>1</sup>Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, <sup>2</sup>The Sixth People's Hospital of Shenyang, Shenyang, China, <sup>3</sup>Hepatology Hospital of Jilin Province, Jilin, China, <sup>4</sup>Henan Provincial People's Hospital, Zhengzhou, China, <sup>5</sup>Tianjing 3rd Central Hospital, Tianjing, China, <sup>6</sup>The 3rd People's Hospital of Taiyuan, Taiyuan, China, <sup>7</sup>Bristol-Myers Squibb, Shanghai, China, <sup>8</sup>GCP ClinPlus Co., Ltd., Beijing, China, <sup>9</sup>Beijing Friendship Hospital, Capital Medical University, Beijing, China
- PGI30 L9** *pgA227* **RIBAVIRIN DOES NOT IMPACT HEALTH-RELATED QUALITY OF LIFE (HRQL) IN PATIENTS ON OMBITASVIR/ PARITAPREVIR /RITONAVIR AND DASABUVIR AT THE END OF 12-WEEK TREATMENT IN TREATMENT-NAÏVE ADULTS WITH GENOTYPE 1A (GT1A) CHRONIC HEPATITIS C**  
**Liu Y**<sup>1</sup>, Bernstein D<sup>2</sup>, Larsen L<sup>1</sup>, Luo Y<sup>1</sup>, Xie Y<sup>1</sup>, Juday T<sup>1</sup>,<sup>1</sup>AbbVie Inc, North Chicago, IL, USA, <sup>2</sup>North Shore University Hospital, Manhasset, IL, USA
- PGI31 L10** *pgA227* **HEALTH-RELATED QUALITY OF LIFE (HRQL) IN PATIENTS ON OMBITASVIR/ PARITAPREVIR /RITONAVIR AND DASABUVIR AT THE END OF 12-WEEK TREATMENT IN TREATMENT-NAÏVE ADULTS WITH GENOTYPE 1B (GT1B) CHRONIC HEPATITIS C**  
**Liu Y**<sup>1</sup>, Bernstein D<sup>2</sup>, Larsen L<sup>1</sup>, Cohen D<sup>1</sup>, Xie Y<sup>1</sup>, Juday T<sup>1</sup>,<sup>1</sup>AbbVie Inc, North Chicago, IL, USA, <sup>2</sup>North Shore University Hospital, Manhasset, IL, USA
- PGI32 L11** *pgA227* **DEVELOPMENT AND VALIDATION OF A CLOSTRIDIUM DIFFICILE QUALITY OF LIFE QUESTIONNAIRE**  
**Garey K**<sup>1</sup>, Aitken S<sup>2</sup>, Gschwind L<sup>3</sup>, Goddu S<sup>4</sup>, Xie Y<sup>5</sup>, Duff C<sup>6</sup>, Shah DN<sup>7</sup>,<sup>1</sup>University of Houston, Houston, TX, USA, <sup>2</sup>MD Anderson Cancer Center, Houston, TX, USA, <sup>3</sup>Hôpitaux Universitaires de Genève, Geneva, Switzerland, <sup>4</sup>St. Luke's Episcopal Hospital, Houston, TX, USA, <sup>5</sup>Merck & Co., Inc, Whitehouse Station, NJ, USA, <sup>6</sup>The Fecal Transplant Foundation, Houston, TX, USA, <sup>7</sup>Department of Clinical Sciences and Administration University of Houston College of Pharmacy, Houston, TX, USA
- PGI33 L12** *pgA227* **SYSTEMATIC REVIEW OF QUALITATIVE STUDIES TO IDENTIFY HEALTH RELATED QUALITY OF LIFE CONSTRUCTS REPORTED BY PATIENTS WITH HEPATITIS C**  
**Mhatre SK**, Sangsiry SS,<sup>1</sup>University of Houston, Houston, TX, USA

---

### GASTROINTESTINAL DISORDERS - Health Care Use & Policy Studies

- PGI34 L13** *pgA227* **DO PHYSICIANS CHANGE THEIR PRESCRIPTIONS IN RESPONSE TO FINANCIAL INCENTIVES**  
**Han E**<sup>1</sup>, Park S<sup>2</sup>,<sup>1</sup>Yonsei University, Incheon, South Korea, <sup>2</sup>Korea Institute of Health and Social Affairs, Seoul, South Korea
- PGI35 L14** *pgA227* **A DESCRIPTIVE ANALYSIS OF A REAL-WORLD POPULATION WITH CHRONIC HEPATITIS C (CHC) TREATED WITH SIMEPREVIR (SMV)- AND/OR SOFOSBUVIR (SOF)-BASED REGIMENS: FINDINGS FROM A US PAYER DATABASE**

Forlenza J<sup>1</sup>, Fortier J<sup>2</sup>, **Laliberté F<sup>2</sup>**, Lefebvre P<sup>2</sup>, Tandon N<sup>1,1</sup>, Janssen Scientific Affairs, LLC, Titusville, NJ, USA, <sup>2</sup>Groupe d'analyse, Ltée, Montreal, QC, Canada

**PGI36 L15 pgA228 SPENDING ON HEPATITIS C ANTIVIRALS IN THE UNITED STATES, 2008-2014**

**Suda KJ<sup>1</sup>**, Hunkler RJ<sup>2</sup>, Matusiak L<sup>2</sup>, Vermeulen L<sup>3</sup>, Schumock G<sup>4,1</sup>, Department of Veterans Affairs and University of Illinois at Chicago, Hines, IL, USA, <sup>2</sup>IMS Health, Plymouth Meeting, PA, USA, <sup>3</sup>UW Hospital and Clinics, Madison, WI, USA, <sup>4</sup>University of Illinois at Chicago, Chicago, IL, USA

**INFECTION - Clinical Outcomes Studies**

**PIN1 L16 pgA228 ANALYSIS OF ADVERSE DRUG REACTIONS DURING PHARMACOTHERAPEUTIC FOLLOW-UP OF HIV+ PATIENTS**

**Reis HP<sup>1</sup>**, Cândido Dd<sup>2</sup>, Oliveira Jd<sup>2</sup>, Araújo SR<sup>2</sup>, Francelino EV<sup>2</sup>, Fonteles MM<sup>2,1</sup>, UFC, Fortaleza, Brazil, <sup>2</sup>Federal University of Ceará, Fortaleza, Brazil

**PIN2 L17 pgA228 ASSESSMENT OF NEPHROTOXICITY AND COST IMPLICATIONS OF COLISTIN THERAPY IN ICU PATIENTS**

Priyendu A<sup>1</sup>, Nagappa AN<sup>2</sup>, Varma M<sup>1</sup>, K E V<sup>1</sup>, **Prabhu NN<sup>3</sup>**, Madzaric M<sup>4,1</sup>, Manipal University, Manipal, India, <sup>2</sup>Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, <sup>3</sup>Manipal College of Pharmaceutical sciences, Manipal University, Manipal, India, <sup>4</sup>University of Banja Luka, Banja Luka, India

**PIN3 L18 pgA228 ANIDULAFUNGIN IN COMPARISON TO FLUCONAZOLE, AMPHOTERICIN B DEOXYCHOLATE, AMPHOTERICIN B LIPOSOMAL, CASPOFUNGIN AND MICALFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDIASIS AMONG NON-NEUTROPENIC PATIENTS ABOVE 16 YEARS: BAYESIAN MIXED TREATMENT COMPARISON (MTC)**

**Diaz JA<sup>1</sup>**, Huerfano C<sup>1</sup>, Niño CP<sup>1</sup>, Alzate JP<sup>1</sup>, Urrego-Novoa JR<sup>1</sup>, Moreno JA<sup>2</sup>, Prieto VA<sup>3,1</sup>, Universidad Nacional de Colombia, Bogota, Colombia, <sup>2</sup>Salud Total EPS, Bogotá D.C., Colombia, <sup>3</sup>Pfizer SAS, Bogota, Colombia

**PIN5 M1 pgA228 SERIOUS ADVERSE EVENTS IN CANADIAN CHILDREN RECEIVING PALIVIZUMAB FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS INFECTION**

**Chan P<sup>1</sup>**, Chen J<sup>1</sup>, Paes B<sup>2</sup>, Mitchell I<sup>3</sup>, Li A<sup>1</sup>, Lanctôt K<sup>1,1</sup>, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, <sup>2</sup>McMaster University, Hamilton, ON, Canada, <sup>3</sup>University of Calgary, Calgary, AB, Canada

**PIN6 M2 pgA229 HIGH DOSE VANCOMYCIN LOADING VERSUS LOW DOSE IS ASSOCIATED WITH DECREASED NEPHROTOXICITY IN EMERGENCY DEPARTMENT SEPSIS PATIENTS**

**Rosini JM<sup>1</sup>**, Davis JJ<sup>2</sup>, Muenzer J<sup>2</sup>, Levine BJ<sup>1</sup>, Comer D<sup>1</sup>, Arnold R<sup>1,1</sup>, Christiana Care Health System, Newark, DE, USA, <sup>2</sup>Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

**PIN7 M3 pgA229 SAFETY PROFILE OF FLUOROQUINOLONES: ANALYSIS OF ADVERSE DRUG REACTIONS IN RELATION TO CONSUMPTION DATA USING PHARMACOVIGILANCE DATABASE IN HEBEI, CHINA**

Shi LW<sup>1</sup>, **Han S<sup>1</sup>**, Zhao YL<sup>2</sup>, Guan XD<sup>1,1</sup>, International Research Center of Medical Administration, Peking University, Beijing, China, <sup>2</sup>School of Pharmaceutical Sciences, Peking University, Beijing, China

**PIN8 M4 pgA229 THE METABOLIC CO-MORBIDITIES PREVALENCE AND RELATED TREATMENT COSTS BETWEEN HAART TREATED AND NOT TREATED HIV INFECTED PATIENTS IN TAIWAN**

**Chang CJ<sup>1</sup>**, Chou T<sup>1</sup>, Fann CS<sup>2,1</sup>, Chang Gung University, Kwei Shan, Tao Yuan, Taiwan, <sup>2</sup>Academia Sinica, Taipei, Taiwan

**PIN9 M5 pgA229 INCREASING PREVALENCE OF CTX-M, TEM AND SHV BETA-LACTAMASES IN CLINICAL PATHOGENIC E. COLI CAUSES SIGNIFICANT HEALTH AND ECONOMIC LOSSES- A PERSPECTIVE FROM PAKISTAN**

**Hussain T<sup>1</sup>**, Jamal M<sup>1</sup>, Nighat F<sup>2</sup>, Andleeb S<sup>1,1</sup>, National University of Sciences and Technology, Islamabad, Pakistan, <sup>2</sup>Riphah International University, Rawalpindi, Pakistan

**PIN10 M6 pgA229 ANALYSIS OF RISK FACTORS OF DEATH IN H1N1 INFLUENZA PATIENTS IN A TERTIARY CARE HOSPITAL**

**Singh A<sup>1</sup>**, Agarwal J<sup>1</sup>, Khera K<sup>1</sup>, Thunga G<sup>2</sup>, Awasthi S<sup>1</sup>, Francis JM<sup>1,1</sup>, Manipal College of Pharmaceutical Sciences, Manipal, India, <sup>2</sup>Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India

**PIN11 M7 pgA229 ASSESSING OUTCOMES WITH CEFTAROLINE TREATMENT COMPARED WITH STANDARD OF CARE AMONG HOSPITALIZED PATIENTS WITH COMPLICATED SKIN AND SKIN-STRUCTURE INFECTIONS (CSSSI)**

**Karve S**, Hackett J, Levinson J, AstraZeneca, Gaithersburg, MD, USA

**PIN12 M8 pgA230 HEALTH IMPACT OF TRIVALENT, TRIVALENT HIGH DOSE AND QUADRIVALENT INFLUENZA VACCINES IN OLDER ADULTS IN ONTARIO, CANADA**

**Cheng X<sup>1</sup>**, Roiz J<sup>2,1</sup>, City University London, London, UK, <sup>2</sup>Creativ-Ceutical, London, UK

**PIN13 M9 pgA230 CLINICAL EFFECT AND THERAPEUTIC DRUG MONITORING OF VANCOMYCIN TREATMENT ON NEONATAL BACTERIAL SEPSIS**

**Tang L**, Suzhou Municipal Hospital, Suzhou, China

**PIN14 M10 pgA230 UNDERSTANDING THE AVERAGE SVR RATES OF HEPATITIS C TREATMENTS AND THEIR IMPLICATIONS ON CLINICAL AND ECONOMIC OUTCOMES: THEN VS. NOW**

**Liberatore C<sup>1</sup>**, Hawryluk E<sup>1</sup>, Lee K<sup>2</sup>, O'Connell E<sup>2</sup>, Faulkner E<sup>3,1</sup>, Quintiles Consulting, New York, NY,



USA, <sup>2</sup>Quintiles Consulting, Cambridge, MA, USA, <sup>3</sup>Quintiles Consulting, Durham, NC, USA

- PIN15 M11 pgA230 COMPARATIVE EFFECTIVENESS OF CLOSTRIDIAL COLLAGENASE OINTMENT FOR THE TREATMENT OF VENOUS LEG ULCERS IN OUTPATIENT CARE SETTINGS**  
**Gilligan AM**<sup>1</sup>, Waycaster CR<sup>1</sup>, Carter M<sup>2</sup>, Fife CE<sup>3</sup>, <sup>1</sup>Smith & Nephew Inc., Fort Worth, TX, USA, <sup>2</sup>Strategic Solutions Inc., Cody, WY, USA, <sup>3</sup>Intellicure, The Woodlands, TX, USA
- PIN16 M12 pgA230 RELATIVE EFFICACY OF SIMEPREVIR (SMV) VERSUS TELAPREVIR (TPV) IN THE TREATMENT OF NAÏVE GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS, BASED ON INDIRECT COMPARISON USING PATIENT-LEVEL CLINICAL TRIAL DATA**  
**Diels J**<sup>1</sup>, Thilakarathne P<sup>2</sup>, Van Sanden S<sup>1</sup>, Sbarigia U<sup>3</sup>, Mehnert A<sup>4</sup>, <sup>1</sup>Janssen Research & Development, Beerse, Belgium, <sup>2</sup>Janssen Infectious Diseases BVBA, Beerse, Belgium, <sup>3</sup>Janssen Global Services, Beerse, Belgium, <sup>4</sup>Janssen EMEA, Beerse, Belgium
- PIN17 M13 pgA231 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF TEDIZOLID FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)**  
McCool R<sup>1</sup>, Eales J<sup>1</sup>, Barata T<sup>2</sup>, Arber M<sup>1</sup>, Cikalo M<sup>1</sup>, Fleetwood K<sup>2</sup>, Glanville J<sup>3</sup>, Gould I<sup>4</sup>, **Kauf T**<sup>5</sup>, <sup>1</sup>York Health Economics Consortium, Ltd, Heslington, UK, <sup>2</sup>Quantics Consulting Ltd, Edinburgh, UK, <sup>3</sup>York Health Economics Consortium, York, UK, <sup>4</sup>Royal Infirmary, Aberdeen, UK, <sup>5</sup>Cubist Pharmaceuticals, Lexington, MA, USA
- PIN18 M14 pgA231 CLINICAL COMPARISON OF FULL COURSE INTRAVENOUS OR ABBREVIATED ORAL ANTIBIOTICS IN HOSPITALIZED PATIENTS WITH METHICILLIN-RESISTANT S. AUREUS (MRSA) SKIN AND SOFT TISSUE INFECTIONS**  
**Jacobs DM**<sup>1</sup>, Hsiao CB<sup>2</sup>, Paladino JA<sup>1</sup>, <sup>1</sup>University at Buffalo, Buffalo, NY, USA, <sup>2</sup>Allegheny General Hospital, Pittsburgh, NY, USA
- PIN19 M15 pgA231 RESPIRATORY RELATED HOSPITALIZATIONS IN PREMATURE INFANTS PROPHYLAXED WITH PALIVIZUMAB IN THE CANADIAN REGISTRY OF PALIVIZUMAB (CARESS)**  
**Abraha HY**<sup>1</sup>, Li A<sup>1</sup>, Paes B<sup>2</sup>, Mitchell I<sup>3</sup>, Lanctôt K<sup>1</sup>, <sup>1</sup>Sunnybrook Health Sciences Centre, Toronto, ON, Canada, <sup>2</sup>McMaster University, Hamilton, ON, Canada, <sup>3</sup>University of Calgary, Calgary, AB, Canada
- PIN21 M16 pgA231 MODELING SURVIVAL IMPACT OF HAZARDOUS DRINKING AND TREATMENT TO REDUCE HAZARDOUS DRINKING AMONG INDIVIDUALS WITH HIV INFECTION: A MONTE CARLO SIMULATION MODEL**  
**Hu X**, Cook RL, University of Florida, Gainesville, FL, USA
- PIN22 M17 pgA231 PHARMACOEPIDEMOLOGY OF CLOSTRIDIAL COLLAGENASE OINTMENT FOR THE TREATMENT OF DIABETIC FOOT ULCERS IN OUTPATIENT CARE SETTINGS**  
**Gilligan AM**, Waycaster CR, Smith & Nephew Inc., Fort Worth, TX, USA
- PIN23 M18 pgA231 PHARMACOEPIDEMOLOGY OF CLOSTRIDIAL COLLAGENASE OINTMENT FOR THE TREATMENT OF PRESSURE ULCERS IN OUTPATIENT CARE SETTINGS**  
**Gilligan AM**, Waycaster CR, Smith & Nephew Inc., Fort Worth, TX, USA
- PIN24 N1 pgA232 LINEZOLID PRESCRIPTION PATTERN: IDENTIFYING THE USE TO RATIONALIZE THE PRACTICE**  
**Reis HP**<sup>1</sup>, Candido D<sup>2</sup>, Magalhaes D<sup>3</sup>, Vieira JB<sup>3</sup>, Sartori DP<sup>3</sup>, Rodrigues JL<sup>2</sup>, Rodrigues EX<sup>3</sup>, Gurgel Filho N<sup>3</sup>, Viana A<sup>3</sup>, Chaves E<sup>3</sup>, Bastos A<sup>3</sup>, Albuquerque I<sup>3</sup>, <sup>1</sup>UFC, Fortaleza, Brazil, <sup>2</sup>Universidade Federal do Ceará, Fortaleza, Brazil, <sup>3</sup>UNIMED Fortaleza, Fortaleza, Brazil
- PIN25 N2 pgA232 PHARMACOEPIDEMOLOGY OF CLOSTRIDIAL COLLAGENASE OINTMENT FOR THE TREATMENT OF VENOUS LEG ULCERS IN OUTPATIENT CARE SETTINGS**  
**Gilligan AM**, Waycaster CR, Smith & Nephew Inc., Fort Worth, TX, USA
- PIN26 N3 pgA232 ANNUAL INCIDENCE RATES OF HERPES ZOSTER AMONG AN IMMUNOCOMPETENT POPULATION IN THE UNITED STATES**  
**Johnson BH**<sup>1</sup>, Gatwood J<sup>2</sup>, Palmer LA<sup>3</sup>, Lenhart G<sup>1</sup>, Kawai K<sup>4</sup>, Acosta CJ<sup>4</sup>, <sup>1</sup>Truven Health Analytics, Cambridge, MA, USA, <sup>2</sup>University of Tennessee Health Science Center College of Pharmacy, Memphis, MA, USA, <sup>3</sup>Truven Health Analytics, Bethesda, MD, USA, <sup>4</sup>Merck & Co., Inc., West Point, PA, USA
- PIN27 N4 pgA232 EXAMINATION OF HOSPITAL-ACQUIRED INFECTIVE ENDOCARDITIS USING MEDICARE CLAIMS DATA**  
Wang Z, Zhang Q, **Miyasato G**, Trinity Partners, LLC, Waltham, MA, USA
- PIN28 N5 pgA232 ONCE-DAILY SINGLE-TABLET REGIMEN REDUCE LOSS TO FOLLOW-UP IN PEOPLE LIVING WITH HIV**  
**Valenzuela-Lara M**<sup>1</sup>, Magis-Rodríguez CL<sup>1</sup>, Bautista-Arredondo S<sup>2</sup>, <sup>1</sup>National Center for the Prevention and Control of HIV and Aids of Mexico (CENSIDA), Distrito Federal, Mexico, <sup>2</sup>National Institute of Public Health of Mexico (INSP), Cuernavaca, Mexico
- PIN29 N6 pgA232 COMPARING FIRST- AND SECOND-SEASON PALIVIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMODYNAMICALLY SIGNIFICANT CONGENITAL HEART DISEASE IN THE CARESS DATABASE (2005-2014)**  
**Li A**<sup>1</sup>, Paes B<sup>2</sup>, Mitchell I<sup>3</sup>, Lanctôt K<sup>1</sup>, <sup>1</sup>Sunnybrook Health Sciences Centre, Toronto, ON, Canada, <sup>2</sup>McMaster University, Hamilton, ON, Canada, <sup>3</sup>University of Calgary, Calgary, AB, Canada
- PIN30 N7 pgA233 DETERMINANTS OF PERTUSSIS OUTBREAKS AND LESSONS LEARNT**  
Millier A<sup>1</sup>, Briquet B<sup>1</sup>, Khemiri A<sup>2</sup>, Roiz J<sup>3</sup>, **Toumi M**<sup>4</sup>, <sup>1</sup>Creativ-Ceutical, Paris, France, <sup>2</sup>Creativ-Ceutical, Chicago,

IL, USA, <sup>3</sup>Creativ-Ceutical, London, UK, <sup>4</sup>University of Marseille, Marseille, France

**PIN31 N8 pgA233 SURVIVAL ANALYSIS OF HIV AND AIDS TREATMENT IN KENYA**

**Owiti EA**, The University of Nairobi, Nairobi, Kenya

## **INFECTION - Cost Studies**

**PIN32 N9 pgA233 USE OF ORITAVANCIN FOR THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS: A UK HOSPITAL BUDGET IMPACT ANALYSIS**

**Wu C**<sup>1</sup>, Jensen IS<sup>1</sup>, Cyr PL<sup>1</sup>, Fan W<sup>2</sup>, Mitchell M<sup>2</sup>, Sulham K<sup>2</sup>, Nathwani D<sup>3</sup>, <sup>1</sup>ICON plc, Cambridge, MA, USA, <sup>2</sup>The Medicines Company, Parsippany, NJ, USA, <sup>3</sup>Ninewells Hospital & Medical School, Dundee, UK

**PIN33 N10 pgA233 A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF FIDAXOMICIN FOR TREATING CLOSTRIDIUM DIFFICILE PATIENTS IN GERMANY**

**Watt M**<sup>1</sup>, McCrea C<sup>2</sup>, Johal S<sup>3</sup>, Posnett J<sup>2</sup>, Nazir J<sup>1</sup>, <sup>1</sup>Astellas, Surrey, UK, <sup>2</sup>Heron Commercialization, London, UK, <sup>3</sup>Parexel International, London, UK

**PIN34 N11 pgA233 COST-UTILITY ANALYSIS OF THREE TYPES OF INFLUENZA VACCINES (TRIVALENT, TRIVALENT HIGH DOSE AND QUADRIVALENT) IN ADULTS AGED 65 AND OLDER UNDER UNIVERSAL INFLUENZA IMMUNIZATION PROGRAM (UIIP) IN ONTARIO, CANADA**

**Cheng X**<sup>1</sup>, Roiz J<sup>2</sup>, <sup>1</sup>City University London, London, UK, <sup>2</sup>Creativ-Ceutical, London, UK

**PIN35 N12 pgA234 COMPARATIVE ANALYSIS OF HIV ANTIRETROVIRAL DRUGS APPROVALS AND PRICES IN THE US AND SAUDI ARABIA**

**Alzarea Al**<sup>1</sup>, Alharbi A<sup>1</sup>, Algarni M<sup>1</sup>, Seoane-Vazquez E<sup>1</sup>, Rodriguez-Monguio R<sup>2</sup>, <sup>1</sup>MCPHS University, Boston, MA, USA, <sup>2</sup>University of Massachusetts, Amherst, Amherst, MA, USA

**PIN37 N13 pgA234 ECONOMIC ASPECTS OF INFLUENZA VACCINATION IN UKRAINE**

**Leleka M**<sup>1</sup>, Zalis'ka O<sup>1</sup>, Paparyha V<sup>2</sup>, Kosyachenko K<sup>3</sup>, <sup>1</sup>Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, <sup>2</sup>Kyiv National Economic University, Kyiv, Ukraine, <sup>3</sup>HTA Ukraine, Kyiv, Ukraine

**PIN38 N14 pgA234 COST-UTILITY ANALYSIS OF INFLUENZA VACCINES FROM SOCIETAL PERSPECTIVE: A COMPARISON OF THE HUMAN CAPITAL APPROACH AND FRICTION COSTS APPROACH IN THE VALUATION OF PRODUCTIVITY COSTS AMONG SENIORS IN ONTARIO CANADA**

**Cheng X**<sup>1</sup>, Roiz J<sup>2</sup>, <sup>1</sup>City University London, London, UK, <sup>2</sup>Creativ-Ceutical, London, UK

**PIN39 N15 pgA234 BURDEN OF DISEASE AND ECONOMIC IMPACT OF MALARIA IN COLOMBIA, 2012**

**Chaparro-Narváez PE**, Diaz D, Castañeda-Orjuela C, de la Hoz F, Instituto Nacional de Salud, Bogotá DC, Colombia

**PIN40 N16 pgA234 IMPACT OF SURGICAL SITE INFECTIONS FOLLOWING COMMON AMBULATORY PROCEDURES ON HEALTHCARE COSTS**

**Olsen MA**<sup>1</sup>, Tian F<sup>2</sup>, Wallace AE<sup>2</sup>, Nickel KB<sup>1</sup>, Warren DK<sup>1</sup>, Fraser VJ<sup>1</sup>, Hamilton BH<sup>1</sup>, <sup>1</sup>Washington University, St. Louis, DE, USA, <sup>2</sup>Healthcore Inc., Wilmington, DE, USA

**PIN41 N17 pgA234 RECENT TRENDS IN URGENT ANTIBACTERIAL THREAT-RELATED HOSPITALIZATION IN THE US**

**Reese ES**, Kurosky SK, Candrilli S, RTI Health Solutions, Research Triangle Park, NC, USA

**PIN42 N18 pgA235 DIRECT MEDICAL COSTS AND ASSOCIATED FACTORS IN PATIENTS WITH CHRONIC HEPATITIS B IN GUGNGZHOU, CHINA: A FIVE-YEAR RETROSPECTIVE COHORT STUDY**

Gao Y<sup>1</sup>, Jia W<sup>2</sup>, Zhou S<sup>1</sup>, Xiao G<sup>2</sup>, Li Y<sup>2</sup>, Zhang J<sup>1</sup>, Ke W<sup>1</sup>, Zhang C<sup>1</sup>, **Yang Y**<sup>1</sup>, <sup>1</sup>Guangdong Pharmaceutical University, Guangzhou, China, <sup>2</sup>Guangzhou Eighth People's Hospital, Guangzhou, China

**PIN43 O1 pgA235 BURDEN AND PREDICTORS OF HOSPITALIZATION COSTS ASSOCIATED WITH ANTI-INFECTIVE ADVERSE EVENTS**

**Pawar AM**, McConeghy RO, Caffrey AR, Kogut S, University of Rhode Island, Kingston, RI, USA

**PIN44 O2 pgA235 IMPACT OF DIFFERENT TREATMENT RATES FOR HEPATITIS C INFECTED PATIENTS ON THE EPIDEMIOLOGIC & ECONOMIC BURDEN IN EGYPT**

**Shelbaya A**<sup>1</sup>, Kuznik A<sup>2</sup>, Salem M<sup>3</sup>, Sadik K<sup>4</sup>, Mankoula W<sup>5</sup>, <sup>1</sup>Columbia University, New York, NY, USA, <sup>2</sup>Lagos University, Lagos, Nigeria, <sup>3</sup>Save The Children Egypt, Cairo, Egypt, <sup>4</sup>Brandeis University, Waltham, MA, USA, <sup>5</sup>Egyptian Ministry of Health, Cairo, Egypt

**PIN45 O3 pgA235 ECONOMIC BURDEN OF COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS IN THE PHILIPPINES ITS CLINICAL AND POLICY IMPLICATIONS IN THE CASE RATE PAYMENTS OF THE PHILIPPINE HEALTH INSURANCE CORPORATION**

**Tumanan-Mendoza BA**<sup>1</sup>, Mendoza V<sup>2</sup>, Punzalan FE<sup>3</sup>, Reganit PF<sup>4</sup>, Bacolcol SA<sup>1</sup>, <sup>1</sup>Manila Doctors Hospital; University of the Philippines College of Medicine, Manila, Philippines, <sup>2</sup>De La Salle Health Sciences Institute, Dasmariñas, Cavite, Philippines, <sup>3</sup>Manila Doctors Hospital; University of the Philippines College of Medicine & Philippine General Hospital, Manila, Philippines, <sup>4</sup>University of the Philippines College of Medicine & Philippine General Hospital, Manila, Philippines

**PIN46 O4 pgA235 COSTS AND CHALLENGES ASSOCIATED WITH DIAGNOSIS AND TREATMENT OF INFECTIONS IN HOSPITALIZED PATIENTS: A RETROSPECTIVE US ELECTRONIC HEALTH DATABASE STUDY**

Durtschi AJ<sup>1</sup>, Khangulov VS<sup>2</sup>, **Peyerl FW**<sup>2</sup>, Sammy Y<sup>3</sup>, <sup>1</sup>Abbott Laboratories, Abbott Park, IL, USA, <sup>2</sup>Boston Strategic Partners, Inc., Boston, MA, USA, <sup>3</sup>Abbott Laboratories, Baar, Switzerland

- PIN47 O5 pgA236 TREATMENT COSTS FOR UNCOMPLICATED MALARIA AT A SECONDARY HEALTH CARE FACILITY IN NIGERIA**  
**Ezenduka CC**, Nnamdi Azikiwe University, Awka, Nigeria
- PIN48 O6 pgA236 ASSESSMENT OF THE COSTS AND OUTCOMES OF ANTIRETROVIRAL THERAPY IN ADULT OUTPATIENTS AT A TERTIARY HOSPITAL IN HARARE, ZIMBABWE**  
**Mafirakureva N<sup>1</sup>**, Shoko P<sup>2</sup>, Khoza S<sup>2</sup>, Torpey K<sup>3</sup>, Postma MJ<sup>1</sup>, van Hulst M<sup>4</sup>, <sup>1</sup>University of Groningen, Groningen, The Netherlands, <sup>2</sup>University of Zimbabwe, Harare, Zimbabwe, <sup>3</sup>FHI 360, Abuja, Nigeria, <sup>4</sup>Martini Hospital, Groningen, The Netherlands
- PIN49 O7 pgA236 AN ECONOMIC MODEL TO COMPARE LINEZOLID, VANCOMYCIN, AND TEICoplanin FOR THE TREATMENT OF CONFIRMED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS NOSOCOMIAL PNEUMONIA IN BRAZIL**  
Niederman MS<sup>1</sup>, **Patel D<sup>2</sup>**, Li JZ<sup>3</sup>, Charbonneau C<sup>4</sup>, Ferreira CN<sup>5</sup>, Figueiredo L<sup>5</sup>, Stephens JM<sup>2</sup>, Haider S<sup>6</sup>, <sup>1</sup>Winthrop-University Hospital, Mineola, NY, USA, <sup>2</sup>Pharmerit International, Bethesda, MD, USA, <sup>3</sup>Pfizer, Inc., San Diego, CA, USA, <sup>4</sup>Pfizer Inc, Paris, France, <sup>5</sup>Pfizer Brasil, São Paulo, Brazil, <sup>6</sup>Pfizer Inc, Groton, CT, USA
- PIN50 O8 pgA236 SYSTEMATIC LITERATURE REVIEW TO IDENTIFY COST ESTIMATES OF LIVER DISEASE IN THOSE WITH CHRONIC HEPATITIS C VIRUS (HCV) IN THE UNITED STATES**  
Mauskopf JA<sup>1</sup>, Mitchell S<sup>2</sup>, Samuel M<sup>3</sup>, **Samp JC<sup>4</sup>**, <sup>1</sup>RTI Health Solutions, Research Triangle Park, NC, USA, <sup>2</sup>RTI Health Solutions, Manchester, NC, USA, <sup>3</sup>RTI Health Solutions, Manchester, UK, <sup>4</sup>AbbVie Inc, North Chicago, IL, USA
- PIN51 O9 pgA236 COST-EFFECTIVENESS ANALYSIS OF SOFOSBUVIR BASED COMBINATION THERAPIES AMONG TREATMENT-NAÏVE AND PRE-TREATED PATIENTS WITH HEPATITIS C INFECTION**  
**Gaitonde P<sup>1</sup>**, Yerlikaya NS<sup>2</sup>, Chirikov VV<sup>1</sup>, Shaya FT<sup>3</sup>, <sup>1</sup>University of Maryland, Baltimore, MD, USA, <sup>2</sup>Hacettepe University, Ankara, Turkey, <sup>3</sup>University of Maryland School of Pharmacy, Baltimore, MD, USA
- PIN52 P1 pgA236 A COST-EFFECTIVENESS ANALYSIS OF PRE-EXPOSURE PROPHYLAXIS FOR HIV: A US PAYER PERSPECTIVE**  
**Vaidya N<sup>1</sup>**, Campbell JD<sup>2</sup>, <sup>1</sup>University of Colorado Denver, Aurora, CO, USA, <sup>2</sup>University of Colorado Anschutz Medical Campus, Denver, CO, USA
- PIN53 P2 pgA237 COST-EFFECTIVENESS ANALYSIS OF A PARTIALLY EFFECTIVE HIV VACCINE IN SAN FRANCISCO**  
**Adamson BJ<sup>1</sup>**, Bounthavong M<sup>2</sup>, Kublin JG<sup>3</sup>, Garrison L<sup>1</sup>, <sup>1</sup>University of Washington, Seattle, WA, USA, <sup>2</sup>Univer, SEATTLE, WA, USA, <sup>3</sup>Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- PIN54 P3 pgA237 ROLLING OUT ORAL PRE-EXPOSURE PROPHYLAXIS (PREP) IS A COST-EFFECTIVE HIV PREVENTION STRATEGY AMONG THE LOS ANGELES COUNTY (LAC) MEN WHO HAVE SEX WITH MEN (MSM)**  
**Drabo EF<sup>1</sup>**, Hay JW<sup>1</sup>, Vardavas R<sup>2</sup>, Wagner Z<sup>3</sup>, Sood N<sup>1</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, USA, <sup>2</sup>Rand Corporation, Santa Monica, CA, USA, <sup>3</sup>University of California, Berkeley, Berkeley, CA, USA
- PIN55 P4 pgA237 ECONOMIC ANALYSIS OF EMPIRIC VERSUS DIAGNOSTIC-DRIVEN STRATEGIES FOR IMMUNOCOMPROMISED PATIENTS WITH SUSPECTED ASPERGILLUS INVASIVE FUNGAL INFECTIONS IN CHINA**  
Qin L<sup>1</sup>, **Chen Y<sup>2</sup>**, Leshner B<sup>1</sup>, Liu Q<sup>3</sup>, Charbonneau C<sup>4</sup>, Earnshaw SR<sup>5</sup>, McDade C<sup>5</sup>, Mao N<sup>6</sup>, Gao X<sup>1</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Pfizer Investment Co. Ltd., Beijing, China, <sup>3</sup>Southern Medical University-Nanfeng Hospital, Guangzhou, China, <sup>4</sup>Pfizer Inc, Paris, France, <sup>5</sup>RTI Health Solutions, Research Triangle Park, NC, USA, <sup>6</sup>China Pharmaceutical University, Nanjing, China
- PIN56 P5 pgA237 ECONOMIC EFFECTIVENESS OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF HOSPITALISED PATIENTS WITH PNEUMOCOCCAL COMMUNITY-ACQUIRED PNEUMONIA FROM A SOCIETAL PERSPECTIVE**  
**Belkova YA**, Rachina SA, Kozlov RS, Smolensk State Medical Academy, Smolensk, Russia
- PIN57 P6 pgA237 ECONOMIC IMPACT OF SIMULATION-BASED TRAINING (SBT) FOR CENTRAL VENOUS CATHETER (CVC) INSERTION**  
**Asche CV<sup>1</sup>**, Barker L<sup>2</sup>, Ren J<sup>1</sup>, Kim M<sup>1</sup>, Kirkness CS<sup>1</sup>, McGarvey J<sup>2</sup>, Short J<sup>2</sup>, Vozenilek J<sup>2</sup>, <sup>1</sup>University of Illinois College of Medicine at Peoria, Peoria, IL, USA, <sup>2</sup>Jump Trading Simulation & Education Center and the OSF Healthcare, Peoria, IL, USA
- PIN58 P7 pgA238 COST-EFFECTIVENESS OF ANIDULAFUNGIN FOR THE TREATMENT OF INVASIVE CANDIDIASIS IN COLOMBIA**  
**Diaz JA<sup>1</sup>**, Urrego-Novoa JR<sup>2</sup>, Moreno JA<sup>3</sup>, Huerfano C<sup>2</sup>, Prieto VA<sup>4</sup>, <sup>1</sup>Universidad Nacional de Colombia, Bogotá D.C., Colombia, <sup>2</sup>Universidad Nacional de Colombia, Bogota, Colombia, <sup>3</sup>Salud Total EPS, Bogotá D.C., Colombia, <sup>4</sup>Pfizer SAS, Bogota, Colombia
- PIN59 P8 pgA238 AN ECONOMIC COMPARISON OF LINEZOLID AND VANCOMYCIN FOR THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) RELATED COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS (CSSSI) IN THE KINGDOM OF SAUDI ARABIA**  
Stephens JM<sup>1</sup>, Gao X<sup>1</sup>, **Patel D<sup>1</sup>**, Li JZ<sup>2</sup>, Haider S<sup>3</sup>, <sup>1</sup>Pharmerit International, Bethesda, MD, USA, <sup>2</sup>Pfizer, Inc., San Diego, CA, USA, <sup>3</sup>Pfizer Inc, Groton, CT, USA
- PIN60 P9 pgA238 COST-EFFECTIVENESS ANALYSIS OF OSELTAMIVIR IN THE INFLUENZA PNEUMONIA PREVENTION IN**

## COLOMBIA

Castañeda-Orjuela C, Vargas-Sandoval G, De la Hoz-Restrepo F, Instituto Nacional de Salud, BOGOTA D.C., Colombia

- PIN62 Q1** *pgA238* **PROJECTED COST SAVINGS OF INTRODUCING FECAL MICROBIOTA TRANSPLANT TREATMENT FOR CLOSTRIDIUM DIFFICILE INFECTION IN CANADA**  
Zowall H, Brewer C, Deutsch A, Zowall Consulting Inc., Westmount, QC, Canada
- PIN63 Q2** *pgA238* **ECONOMIC IMPACT OF SOFOSBUVIR BASED REGIMENS IN HEPATITIS C: AN INTERNATIONAL PERSPECTIVE**  
Parekh MH, Dashputre AA, Kamal KM, Mylan School of Pharmacy, Duquesne University, Pittsburgh, PA, USA
- PIN65 Q3** *pgA238* **THE COST EFFECTIVENESS OF A NOVEL HIGH PRICED COMBINATION THERAPY FOR HEPATITIS C IN TREATMENT NAÏVE GENOTYPE 1 INFECTED PATIENTS**  
McGinnis JJ, Hay JW, University of Southern California, Los Angeles, CA, USA
- PIN66 Q4** *pgA239* **COST-EFFECTIVENESS ANALYSIS OF ANIDULAFUNGIN IN THE TREATMENT OF CANDIDEMIA IN CHILE**  
Gutierrez-Ardila MV, Krieger Hitelman D, Solar Tobar F, Pfizer Chile S.A., Santiago, Chile
- PIN67 Q5** *pgA239* **MODELING THE COST-EFFECTIVENESS OF NOVEL DIRECT ACTING ANTIVIRAL (DAA) TREATMENTS IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)**  
McEwan P<sup>1</sup>, Ward T<sup>1</sup>, Webster S<sup>1</sup>, Kalsekar A<sup>2</sup>, Brenner M<sup>3</sup>, Yuan Y<sup>4</sup>,<sup>1</sup>Health Economics and Outcomes Research Ltd, Monmouth, UK, <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA, <sup>3</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK, <sup>4</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA
- PIN68 Q6** *pgA239* **ESTIMATING THE COST-EFFECTIVENESS OF DACLATASVIR REGIMENS FOR PATIENTS WITH ADVANCED CHRONIC HEPATITIS C IN THE UK**  
McEwan P<sup>1</sup>, Webster S<sup>1</sup>, Ward T<sup>1</sup>, Kalsekar A<sup>2</sup>, Yuan Y<sup>3</sup>, Brenner M<sup>4</sup>,<sup>1</sup>Health Economics and Outcomes Research Ltd, Monmouth, UK, <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA, <sup>3</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA, <sup>4</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
- PIN69 Q7** *pgA239* **COMBINING DISEASE TRANSMISSION AND NUMBERS TREATED IN CONVENTIONAL COST-EFFECTIVENESS ANALYSES OF HEPATITIS C TREATMENT IN THE UK**  
McEwan P<sup>1</sup>, Bennett Wilton H<sup>1</sup>, Webster S<sup>1</sup>, Kalsekar A<sup>2</sup>, Yuan Y<sup>3</sup>, Brenner M<sup>4</sup>,<sup>1</sup>Health Economics and Outcomes Research Ltd, Monmouth, UK, <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA, <sup>3</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA, <sup>4</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK
- PIN70 Q8** *pgA239* **SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES OF VACCINES IN CHINA**  
Wen Y<sup>1</sup>, Pan X<sup>1</sup>, Griffiths UK<sup>2</sup>, Pennington M<sup>2</sup>, Yu H<sup>3</sup>, Jit M<sup>2</sup>,<sup>1</sup>Sichuan University, Chengdu, China, <sup>2</sup>London School of Hygiene and Tropical Medicine, London, UK, <sup>3</sup>Chinese Centre for Disease Control and Prevention, Beijing, China
- PIN71 Q9** *pgA240* **COST- EFFECTIVENESS ANALYSIS OF NEVIRAPINE VS. RITONAVIR-BOOSTED LOPINAVIR IN HIV-INFECTED CHILDREN WITH PERIPARTUM NEVIRAPINE EXPOSURE, IN RESOURCE-CONSTRAINED AREAS FROM A PAYER'S PERSPECTIVE**  
Godwin O<sup>1</sup>, Ettienne EB<sup>2</sup>, Brown LM<sup>1</sup>,<sup>1</sup>Chapman University, Irvine, CA, USA, <sup>2</sup>Howard University, Washington, DC, USA
- PIN72 R1** *pgA240* **COST-EFFECTIVENESS ANALYSIS OF VACCINATION AGAINST RABIES IN DOGS IN COLOMBIA**  
Castillo-Rodríguez L, Castañeda-Orjuela CA, De la Hoz-Restrepo F, INSTITUTO NACIONAL DE SALUD, Bogotá, Colombia
- PIN73 R2** *pgA240* **ESTIMATING THE COST-EFFECTIVENESS OF 12 WEEKS OF TREATMENT WITH DACLATASVIR+SOFOBUVIR IN PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 3**  
McEwan P<sup>1</sup>, Ward T<sup>1</sup>, Webster S<sup>1</sup>, Kalsekar A<sup>2</sup>, Brenner M<sup>3</sup>, Yuan Y<sup>4</sup>,<sup>1</sup>Health Economics and Outcomes Research Ltd, Monmouth, UK, <sup>2</sup>Bristol-Myers Squibb, Princeton, NJ, USA, <sup>3</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK, <sup>4</sup>Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA
- PIN74 R3** *pgA240* **COST IMPLICATIONS OF TEDIZOLID USE IN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) FOR HOSPITALS AND MANAGED CARE ORGANIZATIONS (MCOS)**  
Kauf T<sup>1</sup>, Xu P<sup>1</sup>, Zivkovic M<sup>2</sup>, Corvino FA<sup>3</sup>,<sup>1</sup>Cubist Pharmaceuticals, Lexington, MA, USA, <sup>2</sup>Genesis Research, Hoboken, NJ, USA, <sup>3</sup>Genesis Research, LLC, Hoboken, NJ, USA
- PIN75 R4** *pgA240* **HIGH-DOSE INACTIVATED INFLUENZA VACCINE IS ASSOCIATED WITH COST SAVINGS AND BETTER OUTCOMES COMPARED TO STANDARD-DOSE INACTIVATED INFLUENZA VACCINE IN SENIORS**  
Chit A<sup>1</sup>, Becker DL<sup>2</sup>, Diazgranados C<sup>1</sup>, Maschio M<sup>3</sup>, Yau E<sup>1</sup>, Drummond M<sup>4</sup>,<sup>1</sup>Sanofi Pasteur, Swiftwater, PA, USA, <sup>2</sup>Optum, Burlington, ON, Canada, <sup>3</sup>OptumInsight, Burlington, ON, Canada, <sup>4</sup>University of York, Heslington, York, UK
- PIN76 R5** *pgA240* **COST/UTILITY ANALYSIS OF PNEUMOCOCCAL VACCINES PCV13 VERSUS PPSV23 IN ADULTS OVER 18 YEARS OLD IN CHILE**  
Biagini Leandro L<sup>1</sup>, Rojas Ruben R<sup>1</sup>, Fuentealba Francisca F<sup>1</sup>, Pezzani Marcela M<sup>2</sup>,<sup>1</sup>Universidad Mayor, Santiago, Chile, <sup>2</sup>Universidad San Sebastián, Santiago, Chile

---

## INFECTION - Patient-Reported Outcomes & Patient Preference Studies

- PIN78 R6** *pgA241* **PREDICTING HUMAN IMMUNODEFICIENCY VIRUS VETERANS' ADHERENCE TO ANTIRETROVIRAL AGENTS VIA OPTIMAL DATA ANALYSIS**  
**Cheng Y**<sup>1</sup>, Nebeker JR<sup>1</sup>, Knippenberg KA<sup>1</sup>, Nelson RE<sup>1</sup>, Goetz MB<sup>2</sup>, LaFleur J<sup>1</sup>,<sup>1</sup>University of Utah, Salt Lake City, UT, USA, <sup>2</sup>VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA
- PIN79 R7** *pgA241* **THE RELATIONSHIP BETWEEN PATIENT-RELATED FACTORS AND MEDICATION ADHERENCE AMONG NIGERIAN PATIENTS TAKING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY**  
**Nduaguba O**<sup>1</sup>, Soremekun R<sup>2</sup>, Olugbake O<sup>2</sup>, Barner JC<sup>1</sup>,<sup>1</sup>The University of Texas at Austin, Austin, TX, USA, <sup>2</sup>University of Lagos, Lagos, Nigeria
- PIN80 R8** *pgA241* **TRADITIONAL MEDICINE USE AND ITS IMPACT ON ANTIRETROVIRAL THERAPY ADHERENCE AMONG HIV PATIENTS IN ETHIOPIA**  
Legesse B<sup>1</sup>, **Shewamene Z**<sup>2</sup>,<sup>1</sup>Karolinska Institutet, Stockholm, Sweden, <sup>2</sup>University of Gondar, Gondar, Ethiopia
- PIN81 R9** *pgA241* **USE OF HEALTH BELIEF MODEL TO UNDERSTAND KNOWLEDGE, ATTITUDES AND BEHAVIORS OF PEOPLE TOWARDS THE EBOLA OUTBREAK**  
**Vadhariya A**, Sansgiry SS, University of Houston, Houston, TX, USA
- PIN82 S1** *pgA241* **KNOWLEDGE GAPS ABOUT PNEUMONIA IN OLDER ADULTS: BASELINE RESULTS FROM THE PHARMACISTS' PNEUMONIA PREVENTION PROJECT**  
Schafer JJ<sup>1</sup>, Steele D<sup>1</sup>, Marthol MM<sup>2</sup>, Harris LF<sup>2</sup>, **Pizzi LT**<sup>1</sup>,<sup>1</sup>Thomas Jefferson University, Philadelphia, PA, USA, <sup>2</sup>Center in the Park, Philadelphia, PA, USA
- PIN83 S2** *pgA242* **DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT (SKINFECT-PRO) TO STANDARDIZE AND QUALIFY SYMPTOMS OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI)**  
**Powers JH**<sup>1</sup>, Howard K<sup>2</sup>, Saretsky T<sup>2</sup>, Clifford S<sup>2</sup>, Hoffmann SC<sup>3</sup>, Talbot GH<sup>4</sup>, Cimms TA<sup>5</sup>, Llorens L<sup>6</sup>, FNIH Biomarkers Consortium CABP ABSSSI Project Team <sup>3,1</sup>, Leidos Biomedical Research, Inc., North Bethesda, MD, USA, <sup>2</sup>ICON Clinical Research, LLC, San Francisco, CA, USA, <sup>3</sup>Foundation for the National Institutes of Health, Bethesda, MD, USA, <sup>4</sup>Talbot Advisors, LLC, Anna Maria, FL, USA, <sup>5</sup>AstraZeneca, Gaithersburg, MD, USA, <sup>6</sup>Llorens Consultants, Alameda, CA, USA
- PIN84 S3** *pgA242* **COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (CABP): DEVELOPMENT OF A NEW PATIENT-REPORTED OUTCOME (PRO)**  
**Howard K**<sup>1</sup>, Clifford S<sup>1</sup>, Powers JH<sup>2</sup>, Saretsky T<sup>1</sup>, Hoffmann SC<sup>3</sup>, Llorens L<sup>4</sup>, Talbot GH<sup>5</sup>, Cimms TA<sup>6</sup>, FNIH Biomarkers Consortium CABP ABSSSI Project Team <sup>3,1</sup>, ICON Clinical Research, LLC, San Francisco, CA, USA, <sup>2</sup>Leidos Biomedical Research, Inc., North Bethesda, MD, USA, <sup>3</sup>Foundation for the National Institutes of Health, Bethesda, MD, USA, <sup>4</sup>Llorens Consultants, Alameda, CA, USA, <sup>5</sup>Talbot Advisors, LLC, Anna Maria, FL, USA, <sup>6</sup>AstraZeneca, Gaithersburg, MD, USA
- PIN85 S4** *pgA242* **PREFERENCE VALUES FOR HEPATITIS C-RELATED HEALTH STATES FROM MEMBERS OF THE GENERAL PUBLIC IN AUSTRALIA, BRAZIL, FRANCE, ITALY, AND SPAIN**  
Szabo S<sup>1</sup>, **Samp JC**<sup>2</sup>, Levy A<sup>1</sup>, Lane S<sup>1</sup>, Polo Lorduy B<sup>3</sup>,<sup>1</sup>ICON PLC, Vancouver, BC, Canada, <sup>2</sup>AbbVie Inc, North Chicago, IL, USA, <sup>3</sup>FUNDACIÓN JIMÉNEZ DÍAZ, 28040 Madrid, Spain
- PIN86 S5** *pgA242* **SIGNS, SYMPTOMS, AND EXISTING PATIENT-REPORTED OUTCOME (PRO) MEASURES IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP): A COMPREHENSIVE LITERATURE REVIEW**  
**Saretsky T**<sup>1</sup>, Clifford S<sup>1</sup>, Hoffmann SC<sup>2</sup>, Powers JH<sup>3</sup>, Talbot GH<sup>4</sup>, Howard K<sup>1</sup>,<sup>1</sup>ICON Clinical Research, LLC, San Francisco, CA, USA, <sup>2</sup>Foundation for the National Institutes of Health, Bethesda, MD, USA, <sup>3</sup>Leidos Biomedical Research, Inc., North Bethesda, MD, USA, <sup>4</sup>Talbot Advisors, LLC, Anna Maria, FL, USA
- PIN87 S6** *pgA242* **ASSESSING THE IMPACT OF PEGYLATED-INTERFERON/RIBAVIRIN THERAPY DURATION VERSUS VIRAL RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (QOL) OUTCOMES IN CHRONIC HEPATITIS C VIRUS (HCV) PATIENTS, USING MULTIVARIATE MIXED-EFFECTS MODELING**  
Thilakarathne P<sup>1</sup>, Van Sanden S<sup>2</sup>, **Diels J**<sup>2</sup>, Mehnert A<sup>3</sup>,<sup>1</sup>Janssen Infectious Diseases BVBA, Beerse, Belgium, <sup>2</sup>Janssen Research & Development, Beerse, Belgium, <sup>3</sup>Janssen EMEA, Beerse, Belgium
- PIN88 S7** *pgA243* **EVALUATION OF PATIENT REPORTED OUTCOMES (PRO) IN OBESE PATIENTS IN AN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) PHASE 3 TRIAL**  
Corey GR<sup>1</sup>, Gupta K<sup>2</sup>, Henry E<sup>3</sup>, McGinnis E<sup>4</sup>, **Cammarata S**<sup>4</sup>,<sup>1</sup>Duke University Medical Center, Durham, NC, USA, <sup>2</sup>Department of Medicine, Boston VA Healthcare System, West Roxbury, NC, USA, <sup>3</sup>H2O Clinical LLC, Hunt Valley, MD, USA, <sup>4</sup>Melinta Therapeutics, Lincolnshire, IL, USA

---

## INFECTION - Health Care Use & Policy Studies

- PIN90 S8** *pgA243* **WHAT COST-EFFECTIVENESS DEMANDS AND MARKET ACCESS CHALLENGES WILL NOVEL ANTIBIOTICS FOR MDR GNPS APPROVED VIA THE STREAMLINED LPAD PATHWAY FACE?**  
Ascano M<sup>1</sup>, **Stewart T**<sup>1</sup>, Perez-Cheeks B<sup>2</sup>, Holman D<sup>1</sup>, Moore R<sup>3</sup>, Tomich M<sup>4</sup>,<sup>1</sup>Decision Resources Group, Burlington, MA, USA, <sup>2</sup>Decision Resources Group, Exton, PA, USA, <sup>3</sup>Decision Resources Group, Nashville, TN, USA, <sup>4</sup>Decision Resources Group, New York, NY, USA
- PIN91 S9** *pgA243* **TACKLING THE TARIFF FOR SOFOSBUVIR IN HCV – INDISPENSABLE INNOVATION VERSUS BUDGET-BUSTING POTENTIAL**


Vinuesa L<sup>1</sup>, Holman D<sup>2</sup>, Cox J<sup>1</sup>, Ribeiro A<sup>2</sup>,<sup>1</sup>Decision Resources Group, London, UK, <sup>2</sup>Decision Resources Group, Burlington, MA, USA

- PIN92 T1** *pgA243* **PREDICTORS OF VACCINATION AMONG MOTHERS OF INFANTS IN AN APPALACHIAN COMMUNITY**  
Garg R, Meraya A, Kelly K, West Virginia University, Morgantown, WV, USA
- PIN93 T2** *pgA243* **ENCOURAGING ORPHAN DESIGNATION FOR NEW EBOLA TREATMENTS – COULD THIS DO MORE HARM THAN GOOD?**  
Macaulay R, PAREXEL, London, UK
- PIN94 T3** *pgA244* **PROJECTING CHANGES IN TOTAL DAYS OF THERAPY (DOT) IN PATIENTS HOSPITALIZED FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI)**  
Berger A<sup>1</sup>, Kauf T<sup>2</sup>, Oster G<sup>3</sup>,<sup>1</sup>Evidera, Lexington, MA, USA, <sup>2</sup>Cubist Pharmaceuticals, Lexington, MA, USA, <sup>3</sup>Policy Analysis Inc. (PAI) and Managing Co-Director, MINERVA Health Economics Network, Brookline, MA, USA
- PIN95 T4** *pgA244* **THE STUDY OF HEALTHCARE UTILIZATION AMONG HIV-INFECTED POPULATION: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY**  
Li Y, Chen H, Essien EJ, University of Houston, Houston, TX, USA
- PIN96 T5** *pgA244* **ANALYSIS OF PURCHASE OF ANTIBACTERIAL DRUGS WITHIN THE GUARANTEED VOLUME OF FREE MEDICAL AID IN THE REPUBLIC OF KAZAKHSTAN**  
Pichkhadze G, Satbayeva E, Seitliyeva A, Duysenova R, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
- PIN97 T6** *pgA244* **EVALUATION OF ECONOMIC IMPACT OF TUBERCULOSIS CONTROL IN MALAYSIA USING DYNAMIC TRANSMISSION MODEL**  
Fun WH<sup>1</sup>, Wu DB<sup>1</sup>, Cheong YM<sup>1</sup>, Mohamad Noordin N<sup>2</sup>, Lee KK<sup>1</sup>,<sup>1</sup>Monash University Malaysia, Subang Jaya, Malaysia, <sup>2</sup>National Public Health Laboratory, Sungai Buloh, Malaysia
- PIN98 T7** *pgA244* **COST OF ADMINISTRATION OF A SINGLE DOSE OF ROTAVIRUS VACCINE IN CANADA**  
Noorduyn SG, Thommes EW, GlaxoSmithKline, Mississauga, ON, Canada
- PIN99 T8** *pgA244* **RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH MULTI-DRUG RESISTANT ACINETOBACTER BAUMANNII: A SYSTEMATIC REVIEW OF THE LITERATURE**  
Schmier J<sup>1</sup>, Hulme-Lowe C<sup>1</sup>, Klenk J<sup>1</sup>, Sulham K<sup>2</sup>,<sup>1</sup>Exponent, Alexandria, VA, USA, <sup>2</sup>The Medicines Company, Parsippany, NJ, USA
- PIN100 T9** *pgA245* **INCIDENCE AND COST OF SKIN AND SOFT TISSUE INFECTIONS IN THE UNITED STATES**  
Lee GC<sup>1</sup>, Boyd NK<sup>1</sup>, Lawson KA<sup>2</sup>, Frei CR<sup>1</sup>,<sup>1</sup>The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA, <sup>2</sup>The University of Texas at Austin, Austin, TX, USA
- PIN101 U1** *pgA245* **HIV ANTIRETROVIRAL DRUG UTILIZATION AND EXPENDITURES IN MEDICAID 1991-2014**  
Alshehri A<sup>1</sup>, Seoane-Vazquez E<sup>1</sup>, Schneider T<sup>1</sup>, Rodriguez-Monguio R<sup>2</sup>,<sup>1</sup>MCPHS University, Boston, MA, USA, <sup>2</sup>University of Massachusetts, Amherst, Amherst, MA, USA
- PIN102 U2** *pgA245* **ECONOMIC BURDEN OF PERTUSSIS OUTBREAK IS HIGHLY DEPENDENT ON SETTING**  
Briquet B<sup>1</sup>, Millier A<sup>1</sup>, Khemiri A<sup>2</sup>, Roiz J<sup>3</sup>, Toumi M<sup>4</sup>,<sup>1</sup>Creativ-Ceutical, Paris, France, <sup>2</sup>Creativ-Ceutical, Chicago, IL, USA, <sup>3</sup>Creativ-Ceutical, London, UK, <sup>4</sup>University of Marseille, Marseille, France
- PIN103 U3** *pgA245* **A LARGE-SCALE CROSS-SECTIONAL STUDY OF HIV INFECTION AMONG MALE CLIENTS OVER 50 YEARS OLD IN LOW-COST COMMERCIAL SEX VENUES OF GUANGXI, CHINA**  
Wu X<sup>1</sup>, Feng X<sup>2</sup>, Kelly C<sup>3</sup>, Shen Z<sup>1</sup>, Chen H<sup>1</sup>, Lu H<sup>1</sup>, Luo L<sup>1</sup>, Chen L<sup>1</sup>, Ruan Y<sup>4</sup>, Tang Z<sup>1</sup>,<sup>1</sup>Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Nanning, China, <sup>2</sup>West Virginia University, Morgantown, WV, USA, <sup>3</sup>AIDS Care Research Consultant, Pittsburgh, PA, USA, <sup>4</sup>State Key Laboratory for Infectious Disease Prevention and Control (SKLID), Beijing, China, Beijing, China
- PIN104 U4** *pgA245* **CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?: EVIDENCE FROM THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM**  
McCombs J<sup>1</sup>, Tonnu-Mihara I<sup>2</sup>, Matsuda T<sup>1</sup>, McGinnis J<sup>1</sup>, Fox S<sup>1</sup>,<sup>1</sup>University of Southern California, Los Angeles, CA, USA, <sup>2</sup>Veterans Affairs Long Beach Healthcare System, Long Beach, CA, USA
- PIN105 U5** *pgA245* **PNEUMOCOCCAL VACCINATION COVERAGE IN ADULTS WITH HIGH-RISK CONDITIONS: MISSED OPPORTUNITIES CONTINUE**  
Yang HK, Zhang D, Shao C, Grabenstein J, Merck & Co., Inc., West Point, PA, USA
- PIN106 U6** *pgA246* **DRIVERS AND BEHAVIORS OF ADULTS WHO RECEIVED VACCINATION AT DIFFERENT SETTINGS**  
Yang HK<sup>1</sup>, Shao C<sup>1</sup>, Babrowicz J<sup>2</sup>, LaFerriere M<sup>2</sup>, Hahn R<sup>2</sup>, Grabenstein J<sup>1</sup>,<sup>1</sup>Merck & Co., Inc., West Point, PA, USA, <sup>2</sup>Nielsen Healthcare, Rochester, NY, USA
- PIN107 U7** *pgA246* **PAST TRENDS AND CURRENT CHALLENGES IN THE HEPATITIS C REIMBURSEMENT LANDSCAPE: IS HISTORY REPEATING ITSELF?**  
Griffiths EA, Noble LA, HERON Commercialization, PAREXEL, London, UK
- PIN108 V1** *pgA246* **ASSESSING KNOWLEDGE AND ATTITUDE ABOUT EBOLA IN THE US: A CROSS SECTIONAL SURVEY**  
Jamal A<sup>1</sup>, Startzman K<sup>1</sup>, Guy J<sup>1</sup>, Pierce R<sup>1</sup>, Ahmad A<sup>2</sup>, Chang J<sup>3</sup>, Kidd R<sup>1</sup>, Johnson M<sup>1</sup>, Patel I<sup>1</sup>,<sup>1</sup>Shenandoah

University, Winchester, VA, USA, <sup>2</sup>UCSI University, Kuala Lumpur, Malaysia, <sup>3</sup>Samford University, Birmingham, AL, USA

- PIN109 V2** *pgA246* **PROJECT SKANT - STUDY OF ANTIBIOTIC PRESCRIPTION IN COMMUNITY IN SLOVAKIA**  
**Antlova K**<sup>1</sup>, Snopkova M<sup>1</sup>, Foltan V<sup>2</sup>, <sup>1</sup>Faculty of Pharmacy Comenius University, Bratislava, Slovak Republic, <sup>2</sup>Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic
- PIN110 V3** *pgA246* **REAL-WORLD PRACTICE PATTERNS FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS IN EUROPE: A RETROSPECTIVE DATABASE ANALYSIS**  
**Sulham K**, Fan W, Plent S, The Medicines Company, Parsippany, NJ, USA
- PIN111 V4** *pgA247* **HIV TREATMENT STRATEGIES IN EUROPE (EU): ADOPTION OF SINGLE TABLET REGIMEN (STR)**  
**Narayanan S**<sup>1</sup>, Graham CM<sup>2</sup>, Butterworth A<sup>3</sup>, Fernando S<sup>3</sup>, <sup>1</sup>Ipsos Healthcare, columbia, MD, USA, <sup>2</sup>Ipsos Healthcare, Boston, MA, USA, <sup>3</sup>Ipsos Healthcare, London, UK
- PIN112 V5** *pgA247* **REAL-WORLD PRESCRIBING PATTERNS FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS IN THE UNITED STATES: A RETROSPECTIVE DATABASE ANALYSIS**  
**Sulham K**, Fan W, Werner R, The Medicines Company, Parsippany, NJ, USA
- PIN113 V6** *pgA247* **CONCERNS ON WHO GUIDELINES OF TREATING AND PREVENTING HIV INFECTION**  
**Sánchez E**, Rossi F, Fundación IFARMA, Bogotá, Colombia

# RESEARCH POSTER PRESENTATIONS FLOOR PLAN



## Looking for poster presentations online?

The **ISPOR Scientific Presentations Database** is a searchable database of over 31,500 research papers presented at ISPOR meetings since 1998. The database is searchable by disease, topic, meeting, key word and author. To access the database, go to [www.ispor.org](http://www.ispor.org) and click the purple "Scientific Presentations" tab.

**ISPOR**



Scientific Presentations Database

